{
  "0": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies dopamine receptor agonists and their mechanism but does not explicitly state \"adrenergic agonists,\" missing the general pharmacologic class required by the reference; it also introduces \"vasodilators,\" which is less precise in this context."
  },
  "1": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant guideline recommendations, and appropriately discusses rare exceptions without introducing inaccuracies or irrelevant content."
  },
  "2": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies iron absorption and storage as the key process and discusses monitoring iron status, but it omits the reference answer’s focus on electrolyte activity and neuronal/muscular excitability, which are directly relevant to the compound’s molecular action."
  },
  "3": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "4": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies natamycin and its mechanism—binding to ergosterol and disrupting membrane integrity—but does not state that ergosterol synthesis is inhibited, which is the key fact in the reference answer; instead, it explicitly states synthesis is not inhibited, representing a minor error/omission."
  },
  "5": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that PORT is not routinely indicated, and that its use is limited to specific scenarios, with correct discussion of margin status, prior chemotherapy, and guideline recommendations; all additional content is factually correct and clinically relevant."
  },
  "6": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for pathological confirmation before upstaging, and correctly states that stage I–IIIA pathways are appropriate without such confirmation; all additional content is relevant and guideline-based."
  },
  "7": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the primary mechanism as direct agonism at nicotinic acetylcholine receptors, whereas the reference specifies cholinesterase inhibition as the key action. While the answer is detailed and relevant, this represents a moderate factual error regarding the drug’s molecular mechanism."
  },
  "8": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, mechanism of action, and class of drug, but incorrectly names SSTR2 instead of SSTR5 as the primary receptor, missing a key fact; otherwise, the explanation is accurate and relevant."
  },
  "9": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that adjuvant systemic therapy is not routinely indicated after neoadjuvant therapy and R0 resection, whereas the reference answer affirms its indication regardless of age if comorbidities are compensated; this represents a moderate factual omission."
  },
  "10": {
    "score": 2.0,
    "explanation": "2: The model answer provides plausible mechanisms (antimicrobial and anti-inflammatory actions) but fails to state that the precise molecular mechanism is not fully understood, which is the key fact in the reference; it also presents speculative details as established fact, constituting a moderate factual error."
  },
  "11": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that first-line RET inhibitor therapy remains appropriate after initial chemotherapy, which contradicts the reference's key point that these agents are only first-line if given before systemic therapy; otherwise, they are subsequent-line. This represents a moderate factual error, though the rest of the content is accurate and relevant."
  },
  "12": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, the use of tocilizumab, and that the direct molecular target is the interleukin-6 receptor (IL-6R), but does not specify the alpha subunit (IL-6Rα) as in the reference; this is a minor omission."
  },
  "13": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but overemphasizes waiting for molecular profiling before radiotherapy, which is not appropriate when urgent symptom control is needed; it does acknowledge exceptions for neurological instability, but the overall message may delay necessary palliative radiotherapy, representing a moderate omission."
  },
  "14": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by incorrectly stating that adjuvant chemotherapy with trastuzumab is appropriate for metaplastic histology, missing the key exception noted in guidelines; this is a major inaccuracy that could lead to inappropriate treatment."
  },
  "15": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that EGFR mutation status is not relevant, missing the key fact that ALK inhibitor therapy presumes EGFR is negative or unavailable; while it provides some correct background, this is a moderate factual omission."
  },
  "16": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies blepharospasm and explains the mechanism of botulinum toxin (blocking acetylcholine), but it does not match the reference answer's class (serotonin antagonists), thus missing the key fact required by the question."
  },
  "17": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that surveillance frequency does not differ, missing the key fact that post-radiotherapy follow-up is every 3–6 months, while post-surgery it is every 6 months; this is a moderate factual omission, though the rest of the content is accurate and relevant."
  },
  "18": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the clinical scenario and drug but incorrectly names CYP3A4 instead of CYP2C8 as the relevant enzyme, which is a moderate factual error; otherwise, the explanation is accurate and relevant."
  },
  "19": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly explains that the 0.6 cm threshold is a practical guideline rather than an absolute cutoff, and notes that adjuvant therapy may be considered for tumors slightly below 0.6 cm, though with less certainty. There is a minor inaccuracy in suggesting that therapy can be considered for tumors as small as 0.3 cm, which is more permissive than most guidelines, but this does not significantly alter the clinical meaning."
  },
  "20": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly identifies the scenario, agent, and mechanistic uncertainty, but adds extra detail about hydralazine and other agents; the final mechanistic classification is accurate but slightly more verbose than the reference, representing a minor wording inaccuracy."
  },
  "21": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly emphasizing the superiority of ALK inhibitors and guideline recommendations to switch upon detection. However, it omits that completing the current regimen is also an acceptable option per guidelines, thus missing a key point and overstating the preference to switch immediately."
  },
  "22": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, emphasizing the importance and standard of pathologic confirmation, but introduces nuance about feasibility and exceptions that, while accurate and guideline-based, slightly softens the absolute requirement stated in the reference. There are no inaccuracies, but the answer could be interpreted as less definitive than the reference, constituting a minor wording inaccuracy."
  },
  "23": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but overstates the preference for re-resection, whereas the reference emphasizes that both approaches are acceptable and should be individualized; the model omits the nuance that there is no definitive evidence of superiority and does not mention institutional expertise or patient comorbidities as factors, representing a moderate omission."
  },
  "24": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies 5-lipoxygenase as the enzyme class, explains its role in leukotriene synthesis, and provides accurate, relevant extra information without any errors or omissions."
  },
  "25": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides strong rationale and references, but it omits that both completing current therapy or switching are valid options and overstates the need to switch immediately, missing the individualized, case-by-case approach emphasized in the reference."
  },
  "26": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies RNA polymerase as the target, provides accurate clinical context, and explains the mechanism and drug involved (fidaxomicin) without any inaccuracies or omissions."
  },
  "27": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as nitrate vasodilators/nitrovasodilators and accurately describes the mechanism, but does not explicitly use the term \"nitric oxide donors\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "28": {
    "score": 3.0,
    "explanation": "3: The model answer overstates the routine indication for broad molecular profiling in squamous cell carcinoma, failing to note that such testing is generally not standard except in select populations (e.g., never-smokers, young patients), which is a key clinical fact; however, it correctly emphasizes the importance of PD-L1 testing and does not provide unsafe advice."
  },
  "29": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately stating that the precise target is not fully defined and providing clinically relevant detail about the mechanism without introducing inaccuracies."
  },
  "30": {
    "score": 3.0,
    "explanation": "3: The model answer accurately explains that if the lesions are considered T3 multi-nodular disease, management is similar to a single T3, N1 lesion, and it discusses the distinction between metastases and synchronous primaries. However, it does not clearly state that if biopsy confirms synchronous multiple primaries, management may diverge and each lesion must be evaluated individually, which is a key fact in the reference answer."
  },
  "31": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that amivantamab-vmjw use is not contingent on broad profiling, while also emphasizing the importance of comprehensive molecular testing and providing relevant, correct additional context."
  },
  "32": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the molecular target as the interleukin-6 receptor and provides relevant clinical context, but it omits specifying the \"soluble\" and \"alpha subunit\" aspects of the receptor, which are key details in the reference answer."
  },
  "33": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing palliative brain radiotherapy for symptomatic brain metastases and acknowledging the role of systemic therapy; additional details are correct, relevant, and enhance clinical clarity without introducing errors."
  },
  "34": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that adjuvant trastuzumab ± pertuzumab is recommended regardless of initial nodal status, whereas the reference specifies that dual HER2 blockade is indicated only if the initial staging was node-positive; this is a moderate factual error."
  },
  "35": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies mu-opioid receptor agonism for codeine but introduces dextromethorphan’s sigma-1 and NMDA mechanisms, which are not the reference answer’s focus; this dilutes the key fact and adds partially relevant but not required details, covering about 70–89% of the reference content."
  },
  "36": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant explanations, and contains no inaccuracies or omissions."
  },
  "37": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that the combination regimen is restricted to nonsquamous histology, not recommended for squamous cell carcinoma, and that osimertinib monotherapy is preferred for EGFR-mutant squamous cases. Additional content is accurate, relevant, and enhances clarity without introducing errors."
  },
  "38": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, includes supporting guidelines and references, and contains no inaccuracies or omissions."
  },
  "39": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and discusses both VEGF and TNF-α, but ultimately selects TNF-α as the primary target, which is incorrect; the reference specifies VEGF-A. The answer covers some relevant facts but misses the key target, constituting a moderate factual error."
  },
  "40": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and the use of glucocorticoids, but incorrectly names phospholipase A2 as the directly targeted enzyme for anti-inflammatory effects on leukotriene production, rather than the reference answer's lipoxygenase inhibitors; this is a moderate factual inaccuracy."
  },
  "41": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging details, and clearly states that surgery remains appropriate; all additional explanations are correct and clinically relevant."
  },
  "42": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies FXR as the primary target instead of PPAR-delta, which is a moderate factual error, though the mechanistic explanation is otherwise accurate and relevant to cholestatic disease."
  },
  "43": {
    "score": 2.0,
    "explanation": "2: The answer incorrectly identifies the drug as alprostadil rather than papaverine, which is the agent described in the reference; while it discusses the uncertainty of the mechanism, the main factual error is the misidentification of the drug, which is a moderate omission."
  },
  "44": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanism as competitive inhibition of dihydropteroate synthase, blocking PABA incorporation into folate, and links this to impaired DNA replication and cell division, fully covering all key clinical facts in the reference answer with accurate, relevant elaboration."
  },
  "45": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the fibroblast growth factor receptor (FGFR) family as a target but also lists PDGFR and VEGFR, which, while factually correct for nintedanib, are not the specific answer requested; this dilutes focus from the key fact in the reference answer. No unsafe statements are present."
  },
  "46": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including alectinib's superiority over crizotinib for CNS metastases, supporting evidence, and current guideline recommendations, with no inaccuracies or omissions."
  },
  "47": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the glucocorticoid mechanism (inhibition of phospholipase A2 via lipocortin), but does not mention direct inhibition of the lipoxygenase pathway as specified in the reference; it covers most, but not all, key facts."
  },
  "48": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the primary neurotransmitter and receptor (norepinephrine/adrenergic) rather than serotonin/serotonin receptor, which is the key fact in the reference. While the explanation is relevant, this represents a moderate factual error."
  },
  "49": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, the likely drug (ketoconazole), and the mechanism of CYP450 inhibition, but it fails to specify \"Cytochrome P450 17A1 inhibitors\" as required by the reference answer, instead focusing on the general mechanism (competitive inhibition) rather than the specific enzyme class."
  },
  "50": {
    "score": 3.0,
    "explanation": "3: The model answer omits the key fact that cytotoxic chemotherapy is indicated in the setting of visceral crisis, which is the main exception described in the reference answer; while it provides a detailed and accurate discussion of endocrine therapy options, it misses this critical clinical scenario."
  },
  "51": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts, correctly identifying the mechanism as monoamine reuptake inhibition and referencing relevant drugs, but it does not specifically highlight \"serotonin uptake inhibitors\" as the most accurate class per the reference, and introduces broader terminology that may cause minor confusion."
  },
  "52": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of metronidazole’s general mechanism and acknowledges that the precise molecular details are not fully understood, but it does not directly state that the mechanism is \"unknown cellular or molecular interaction\" as required by the reference answer; instead, it offers the best-known classification, thus missing the key fact that the mechanism is officially classified as unknown."
  },
  "53": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies CYP3A4 induction as the mechanism, and provides additional accurate, clinically relevant detail without any inaccuracies or omissions."
  },
  "54": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of RET rearrangements in squamous histology and the lack of direct evidence for RET inhibitors in this group, but it incorrectly states that RET-targeted therapy should not be prioritized, which contradicts the reference's emphasis on applying targeted therapy when actionable alterations are present regardless of histology; this is a moderate omission."
  },
  "55": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of alectinib and discontinuation of current therapy, rather than completing planned systemic therapy first; this is a major inaccuracy and could lead to inappropriate management."
  },
  "56": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains that initial multifocality and prior ineligibility do not preclude concurrent chemoradiation, and emphasizes the importance of current feasibility and absence of prior thoracic radiotherapy; no inaccuracies or omissions are present."
  },
  "57": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts (reduction of disulfide bonds and antioxidant effect), correctly identifies NAC, and provides relevant mechanistic detail. However, it emphasizes glutathione replenishment more than direct reduction activity, which is the principal effect per the reference, representing a minor wording inaccuracy."
  },
  "58": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough clinical explanation and correctly identifies macrolides as the class, but it omits the broader pharmacologic class \"protein synthesis inhibitors\" as required by the reference answer, focusing instead on the subclass; this is a moderate omission."
  },
  "59": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "60": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that palliative chemotherapy assumes absence of metastatic disease, directly contradicting the reference answer's key point; while the explanation is detailed, this is a major inaccuracy that could mislead management."
  },
  "61": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and includes a clear summary table; there are no inaccuracies or omissions."
  },
  "62": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing systemic therapy, explaining the rationale, and appropriately discussing the role of local therapy; all additional details are correct and clinically relevant."
  },
  "63": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes guideline recommendations, and appropriately emphasizes individualized decision-making for T1bN0 HER2-positive tumors; no inaccuracies or omissions are present."
  },
  "64": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "65": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate EGFR TKI initiation and discontinuation of ongoing systemic/maintenance therapy, which is not the standard approach in this scenario; this is a major inaccuracy with potential for clinical harm."
  },
  "66": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that adjuvant radiotherapy is an acceptable alternative when re-excision is not feasible and provides relevant context, but it incorrectly assigns a category 2A recommendation instead of the correct category 2B, which is a moderate factual error regarding the level of evidence."
  },
  "67": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the treatment sequencing, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "68": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies B cell-mediated antigen presentation and autoantibody production as the inhibited pathways, mentions CD20 targeting, and explains the mechanism, but does not explicitly state \"antibody-dependent cytotoxicity\" as in the reference, representing a minor omission."
  },
  "69": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference (mechanism is unknown), correctly identifies iodoquinol, and provides additional, accurate, clinically relevant information about its proposed mechanism (metal chelation), but slightly overstates the certainty of the chelation hypothesis, which is still speculative; this is a minor wording inaccuracy."
  },
  "70": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies P-glycoprotein (ABCB1) and protease inhibitors as most relevant, omitting BCRP and velpatasvir, which are key facts; while the explanation is generally accurate for P-gp, it misses the specific transporter and drug class highlighted in the reference."
  },
  "71": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies IL-1β as the cytokine, and provides additional accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "72": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that surveillance schedules are the same for post-surgical and post-radiotherapy patients, missing the reference's distinction that follow-up is more intensive after radiotherapy; it also omits the specific timing differences (every 3–6 months for 3 years post-RT vs. every 6 months for 2–3 years post-surgery), which is a moderate factual omission."
  },
  "73": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the need for comprehensive profiling and not assuming exclusion of ALK/ROS1 without explicit mention, but it contradicts the reference's implication that EGFR TKI initiation presumes such profiling has occurred, and introduces ambiguity not present in the reference."
  },
  "74": {
    "score": 3.0,
    "explanation": "3: The model answer identifies DNA gyrase as the primary target but incorrectly states that this is the main target in Streptococcus pneumoniae (a Gram-positive organism), where topoisomerase IV is actually the primary target; it covers most key facts but contains a moderate factual inaccuracy."
  },
  "75": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes as the induced class and mentions self- and drug-drug metabolism, but incorrectly specifies CYP3A4 rather than CYP1A as the primary isoenzyme, which is a moderate factual inaccuracy."
  },
  "76": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, lists all required mutations (including those in the reference), correctly states the need for broad profiling regardless of prior radiotherapy, and provides accurate, relevant rationale without inaccuracies or omissions."
  },
  "77": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that adjuvant chemoradiation is standard regardless of mediastinal lymph node dissection, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "78": {
    "score": 3.0,
    "explanation": "3: The model answer covers the uncertainty about the precise mechanism (the key fact), but introduces vancomycin as the main drug, whereas the reference answer refers to metronidazole. This is a moderate factual inaccuracy, as metronidazole is still commonly used in some settings and was the drug referenced in the question. Otherwise, the answer is detailed and relevant."
  },
  "79": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains its role, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary isoform relevant to anti-inflammatory effects, which is a minor omission."
  },
  "80": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference by stating that stable residual abnormalities do not warrant more frequent surveillance, omitting the key fact that any residual or new abnormality after treatment should prompt increased imaging frequency; this is a moderate factual omission."
  },
  "81": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing bisphosphonates/denosumab in the absence of symptoms or fracture risk, and reserving EBRT for symptomatic or high-risk lesions; all additional content is accurate and clinically relevant."
  },
  "82": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the primary mechanism as direct muscarinic receptor activation (as with pilocarpine), rather than cholinesterase inhibition, which is the mechanism described in the question. This is a moderate factual error, though the rest of the explanation is relevant."
  },
  "83": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies povidone-iodine, accurately describes its broad, nonspecific mechanism, and clearly states that the exact molecular mechanism in fungi is not well established, matching ≥90% of the reference content. The extra mechanistic detail is correct and relevant, but the answer could be slightly more concise in directly echoing the reference's emphasis on the mechanism being unknown."
  },
  "84": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant guideline details, and includes accurate rationale without any inaccuracies or omissions."
  },
  "85": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the pharmacological class is \"enzyme inhibitors\" and provides relevant, correct details about benzimidazoles and their mechanism, but it over-specifies the class (benzimidazoles/microtubule inhibitors) rather than the general \"enzyme inhibitors\" required by the question, and introduces some ambiguity by mentioning drugs not used for Guinea worm; this constitutes a minor error and a minor omission."
  },
  "86": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "87": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the principal drug class as interleukin-1 (IL-1) inhibitors and provides relevant explanation, but does not use the exact term \"Interleukin 1 Receptor Antagonists\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "88": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about SABR's safety, efficacy, and patient selection, and contains no inaccuracies or omissions."
  },
  "89": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies GLUT4 as the direct molecular target, whereas the question and reference specify the insulin receptor; although the explanation is detailed, this represents a moderate factual error."
  },
  "90": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional rationale, and includes no inaccuracies or omissions."
  },
  "91": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate context regarding guidelines and rationale, and contains no inaccuracies or omissions."
  },
  "92": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies NAC and thoroughly explains its role as a glutathione precursor and antioxidant, but it does not explicitly use the term \"free radical scavenging activity,\" which is the most direct property referenced in the key answer; otherwise, all key facts are present."
  },
  "93": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference (\"nucleic acid synthesis inhibitors\"), correctly identifies the mechanism (inhibition of nucleotide synthesis), and provides accurate, clinically relevant elaboration without inaccuracies or omissions."
  },
  "94": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed discussion of cytokines/interferons and anti-VEGF agents, but it does not identify \"biological response modifiers\" as the class, which is the key fact in the reference. It covers some relevant mechanisms but introduces moderate factual confusion and does not directly answer the question as required."
  },
  "95": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging, management implications, and when systemic therapy for metastatic disease is indicated, with no inaccuracies or omissions."
  },
  "96": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the management distinction between N0–1 and N2 disease, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "97": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies ALK1 (ACVRL1) as the primary target instead of ACVR2A, which is specifically targeted by sotatercept and similar agents in PAH. While the explanation is mostly relevant, this represents a moderate factual error regarding the main molecular target."
  },
  "98": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacologic class (protein synthesis inhibitor/lincosamide), explains the mechanism, and provides relevant, accurate additional details without any inaccuracies or omissions."
  },
  "99": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and appropriately emphasizes that best supportive care is standard while acknowledging rare individualized exceptions; there are no inaccuracies or omissions."
  },
  "100": {
    "score": 4.0,
    "explanation": "4: The model answer correctly describes antibody-mediated neutralization as the key molecular process and explains passive immunity, but omits mention of Fc receptor engagement and immune modulation, which are part of the reference answer."
  },
  "101": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but overemphasizes surgery as standard initial management, whereas the reference stresses that induction systemic therapy is generally preferred; this represents a moderate omission and a slight misalignment with current consensus, though the answer is otherwise accurate and not unsafe."
  },
  "102": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, the use of recombinant clotting factor, and its role as a cofactor in the coagulation cascade, but it does not explicitly use the general pharmacological class \"enzyme activators\" as required by the question and reference answer, covering about 70-89% of key facts."
  },
  "103": {
    "score": 4.0,
    "explanation": "4: Covers the key fact of forming a protective barrier (demulcent activity) and explains the mechanism accurately; however, mentioning bismuth subsalicylate and sucralfate as examples is slightly imprecise since sucralfate is not a bismuth compound, but this does not alter the core meaning."
  },
  "104": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "105": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug as a biologic DMARD and TNF inhibitor, covering all but one minor point—the reference answer uses the broader class \"Biological Response Modifiers,\" which the model does not explicitly mention, but the mechanistic and clinical classification is otherwise accurate and complete."
  },
  "106": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the drug, its binding target (alpha-2-delta subunit), and the downstream effect on neurotransmitter release, but it does not explicitly state that the full cellular or molecular mechanism is incompletely characterized, which is the key fact in the reference answer."
  },
  "107": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate details, and contains no inaccuracies or omissions."
  },
  "108": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "109": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional details, cites guidelines, and contains no inaccuracies or omissions."
  },
  "110": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the default classification as metastatic disease and the criteria for considering synchronous primaries, but it overemphasizes the need for pathological/molecular distinction, whereas the reference answer allows management as two primaries if both are resectable and there is no nodal or distant disease; this constitutes a moderate omission."
  },
  "111": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "112": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for endocrine therapy, and provides relevant, guideline-based context without any inaccuracies or omissions."
  },
  "113": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that preoperative systemic therapy is not routinely mandated for cT1cN0 HER2-positive or triple-negative breast cancer and that immediate surgery is standard, but it overemphasizes surgery as the default and underplays that neoadjuvant therapy is a recommended option due to recurrence risk and response assessment; this constitutes a minor omission in prioritization but otherwise covers nearly all key facts."
  },
  "114": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference by stating that treatment can proceed without pathological confirmation, whereas the reference clearly states tissue diagnosis is essential; while the model provides relevant context and cites guidelines, it omits the key fact that imaging alone is insufficient and thus contains a moderate factual error."
  },
  "115": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on dapsone’s anti-neutrophil and myeloperoxidase inhibition, but omits the key fact from the reference: inhibition of PABA utilization in folate synthesis. While the anti-inflammatory effects are relevant, the question specifically asks for the molecular mechanism by which the sulfonamide class acts, which is not directly addressed."
  },
  "116": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the proposed mechanisms of ursodeoxycholic acid, but it does not acknowledge that the precise molecular mechanism is unknown, which is the key fact in the reference answer; otherwise, the content is factually correct and relevant."
  },
  "117": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant chemotherapy is routinely recommended for all eligible patients, whereas observation alone is an appropriate standard option per the reference; this is a moderate factual error. It does provide relevant supporting details but misrepresents the standard of care."
  },
  "118": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough and accurate mechanistic explanation of imiquimod’s immune modulation and downstream effects, but it does not identify RNA replicase as the most direct molecular target, instead naming eIF2α. This misses the specific key fact required by the reference answer."
  },
  "119": {
    "score": 5.0,
    "explanation": "5: Fully correct; identifies tetracyclines as the broad pharmacologic class, matching the reference answer and providing accurate, relevant mechanistic detail."
  },
  "120": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately lists relevant high-risk features, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "121": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides relevant guideline references, but it diverges from the reference by stating it is acceptable to proceed with treatment based on imaging and clinical context if biopsy is not feasible, whereas the reference insists on exhausting all alternative diagnostic modalities before proceeding; this represents a moderate omission regarding the necessity of fully pursuing all possible diagnostic options."
  },
  "122": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of ROS1 rearrangements in squamous tumors and the need for diagnostic confirmation, but it overstates guideline recommendations by implying ROS1 therapy is appropriate regardless of histology, whereas guidelines generally exclude squamous histology except in rare, well-validated cases. This represents a moderate inaccuracy."
  },
  "123": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies β-lactam antibiotics and explains their mechanism, but it does not directly answer the question, which asks for the general pharmacological class (\"enzyme inhibitors\"). Thus, it covers the mechanism but misses the requested level of classification."
  },
  "124": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"receptor tyrosine kinase inhibitors,\" which is a more specific subset of \"protein kinase inhibitors\" and covers all key facts, with only a minor wording difference that does not alter the clinical meaning."
  },
  "125": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes vitamin A’s role in vision and epithelial maintenance but omits the key reference mechanism—antioxidant (free radical scavenging) activity—thus missing a central fact required by the question."
  },
  "126": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts, accurately explains the lack of a single defined molecular target for amiodarone in AF, and provides clinically relevant context without inaccuracies or omissions."
  },
  "127": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the specific class (beta-lactam antibiotics) and accurately describes the mechanism, but it does not directly state the general pharmacological class \"enzyme inhibitors\" as in the reference answer, thus missing a key fact."
  },
  "128": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for durvalumab versus osimertinib, addresses evidence and guidelines, and provides relevant clinical context without inaccuracies or omissions."
  },
  "129": {
    "score": 4.0,
    "explanation": "4: Covers all key facts and provides correct, relevant extra detail, but there is a minor inaccuracy in the surveillance interval wording (\"every 6–12 months for up to 5 years\" vs. reference's \"every 6 months for 2 years, then annually\"), which could cause slight confusion but does not alter the overall meaning."
  },
  "130": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanism as inhibition of fungal protein synthesis by interfering with ribosomal function, matching the reference answer and providing accurate, relevant clinical context without any inaccuracies or omissions."
  },
  "131": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, clearly stating that the precise mechanism is unknown, and accurately describes the proposed central actions of cyclobenzaprine. There is minor extra detail (e.g., serotonin antagonism, table) that is correct and relevant, but the answer could more explicitly emphasize the uncertainty regarding the exact cellular/molecular mechanism."
  },
  "132": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies fluoroquinolones and their inhibition of both DNA gyrase and topoisomerase IV, but it does not specifically state that inhibition of topoisomerase IV is the primary mechanism for the described effect (inhibition of chromosome segregation), as required by the reference answer. The focus on DNA gyrase (topoisomerase II) in Gram-negatives introduces minor inaccuracy for this context."
  },
  "133": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states the recommended surveillance interval (every 3–6 months, typically every 6 months), provides rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "134": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phosphodiesterase 5 (PDE5) as the primary molecular target, explains its role in cGMP hydrolysis, and clearly links PDE5 inhibition to increased cGMP and relevant therapeutic effects in osteoarthritis, fully covering all key clinical facts from the reference."
  },
  "135": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including prioritizing chemoradiation over surgery, rationale regarding margin-negative resection and micrometastatic disease, and guideline/evidence support; additional details are accurate and clinically relevant."
  },
  "136": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines, and provides a clear summary without any inaccuracies or omissions."
  },
  "137": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies muscarinic antagonism as the primary mechanism, whereas the reference specifies dopamine antagonists. While the explanation is detailed and mostly accurate regarding muscarinic pathways, it omits the key fact required by the reference and contains a moderate factual error regarding the main receptor class."
  },
  "138": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies EGFR as the primary molecular target, whereas the reference specifies HER2/neu (erbB-2); while the answer discusses relevant agents and mechanisms, it omits the key fact and contains a moderate factual error regarding the main receptor tyrosine kinase involved."
  },
  "139": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as ACTH receptor (melanocortin 2) activation, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "140": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizes that switching to targeted therapy is reasonable in cases of poor response or toxicity, and acknowledges that completing current therapy is also acceptable if the patient is responding well. There is a minor wording inaccuracy suggesting immediate switch is broadly guideline-endorsed, but this does not significantly alter the clinical meaning."
  },
  "141": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and discusses biologic agents used in JIA, but incorrectly names TNF-α as the molecular target instead of interleukin-1 beta (IL-1β), which is the reference answer; otherwise, the explanation is thorough and relevant."
  },
  "142": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism of action and names hydroxyurea, but it does not explicitly state the broader drug class \"nucleic acid synthesis inhibitors\" as required by the reference answer, covering about 70-89% of key facts."
  },
  "143": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant trials and guidelines, and contains no inaccuracies or omissions."
  },
  "144": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts about the mechanism (nuclear receptor binding, increased fatty acid oxidation, decreased lipogenesis) and discusses relevant receptor classes, but ultimately selects FXR agonists rather than the reference answer of thyroid hormone receptor agonists, representing a moderate factual error."
  },
  "145": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies beta-lactam antibiotics as the class and explains their mechanism, but it omits the broader class term \"enzyme inhibitors\" as in the reference answer, which is the best pharmacological class descriptor requested by the question."
  },
  "146": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites supporting evidence, and contains no inaccuracies or omissions."
  },
  "147": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that SRS alone is preferred even with mild neurological symptoms, whereas the reference specifies that surgical resection is preferred in symptomatic patients; this is a clinically meaningful omission. Otherwise, the answer is thorough and accurate."
  },
  "148": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as nucleoside analogs, explains the mechanism, and provides relevant examples, but does not explicitly state \"DNA polymerase inhibitors\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "149": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains the standard approach (contralateral nodules are usually metastatic), details the rare exception for proven synchronous primaries, and provides relevant guideline references. There are no inaccuracies or omissions."
  },
  "150": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides a nuanced, guideline-based rationale, but it contradicts the reference by stating it is reasonable to proceed without pathologic confirmation, omitting the reference's emphasis that pathology is required whenever feasible; this is a moderate omission."
  },
  "151": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that durvalumab is not recommended for EGFR-mutant NSCLC and that osimertinib is not standard in this setting, but it introduces some ambiguity by emphasizing lack of approval for osimertinib and suggesting observation, which could confuse the prioritization asked in the question; otherwise, it is accurate and thorough."
  },
  "152": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies calcium channel blockers as the drug class, rather than adrenergic alpha-antagonists, and provides an inaccurate molecular mechanism; while the explanation is detailed and relevant to Raynaud's treatment, it does not address the specific mechanism described in the question, resulting in a moderate factual error."
  },
  "153": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing immediate SVC stenting for significant symptoms, and provides additional relevant clinical context without inaccuracies or omissions."
  },
  "154": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies dopamine receptor antagonists as the drug class, whereas the reference specifies dopamine agonists (direct stimulators); although the explanation is detailed and relevant to Tourette syndrome, the primary mechanism and class are not aligned with the reference, constituting a moderate factual error."
  },
  "155": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that the same surveillance schedule is appropriate, directly contradicting the reference, which specifies that closer surveillance (every 3–6 months) is needed after radiotherapy. This is a major inaccuracy that could lead to suboptimal patient care."
  },
  "156": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the primary molecular target and provides accurate, relevant clinical context, but does not specifically single out COX-2 (prostaglandin G/H synthase 2) as the main enzyme, which is a minor omission."
  },
  "157": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, accurately stating that surveillance protocols are generally the same for both groups and providing correct details on frequency and modalities. It includes minor extra detail about tailoring imaging based on prior metastatic sites, which is clinically relevant, but slightly overemphasizes the lack of formal guidelines and the need for individualization, which could be seen as a minor wording inaccuracy."
  },
  "158": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "159": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the glucocorticoid receptor mechanism and pathway, but incorrectly names NF-κB as the primary molecular target, rather than the glucocorticoid receptor itself, which is the direct target of the therapy; this is a moderate factual error."
  },
  "160": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating EGFR TKI therapy is not appropriate with a concurrent KRAS mutation, which is inaccurate and omits the key fact that EGFR mutation status remains the primary driver for targeted therapy selection; this constitutes a major inaccuracy."
  },
  "161": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies chondroitin sulfate, explains its role as a glycosaminoglycan in proteoglycan formation, and details its effects on cartilage metabolism, closely matching the reference. However, the final category phrasing (\"modulation of extracellular matrix synthesis and degradation\") is less precise than \"biological macromolecular activity,\" representing a minor wording inaccuracy."
  },
  "162": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, addresses the nuances of drug approval and guideline recommendations, and contains no inaccuracies or omissions."
  },
  "163": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant facts (EGFR mutation, standard of care, importance of profiling), but incorrectly states that amivantamab-vmjw plus lazertinib is not appropriate without full profiling, which is a moderate factual error. The reference answer clarifies that confirmed EGFR mutation is sufficient for this regimen, so the model's insistence on comprehensive profiling is inaccurate and omits the key point that insufficient tissue does not preclude use."
  },
  "164": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant supporting evidence and preferred regimens without any inaccuracies or omissions."
  },
  "165": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference (mucosal protection, modulation of local environment), and adds correct, relevant details about direct bactericidal action and urease inhibition; however, the reference focuses on acid-base modulation, which is not explicitly emphasized, representing a minor omission in emphasis."
  },
  "166": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, the drug (nintedanib), and its mechanism, but incorrectly names PDGFR instead of VEGFR as the receptor whose inhibition directly reduces fibroblast activity and fibrosis, missing the key fact required by the question."
  },
  "167": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends chemotherapy for a recurrence score of 25, whereas guidelines and the reference specify chemotherapy is generally not recommended below 26; this is a moderate factual error, despite otherwise thorough rationale and supporting evidence."
  },
  "168": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies COX-2 as the molecular target of selective NSAIDs and provides relevant clinical context, but it does not mention COX-1, which is the reference answer's focus, and thus misses a key fact."
  },
  "169": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the necessity of pathological confirmation, details guideline recommendations, and appropriately notes exceptions for unfit patients; there are no inaccuracies or omissions."
  },
  "170": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that non-contrast low-dose chest CT is sufficient for surveillance in this context, and provides correct, relevant guideline-based rationale without any inaccuracies or omissions."
  },
  "171": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for dual HER2 blockade, cites supporting evidence and guidelines, and clearly outlines when single-agent trastuzumab may be considered, with no inaccuracies or omissions."
  },
  "172": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the JAK-STAT pathway and the general mechanism but incorrectly specifies interferon-gamma receptor instead of interferon alpha receptor, missing the precise molecular target required by the reference answer."
  },
  "173": {
    "score": 1.0,
    "explanation": "1: The model answer contradicts the reference by incorrectly stating that local therapy alone is not appropriate, omitting the key fact that local therapy can be considered as initial treatment in carefully selected oligometastatic NSCLC patients; this is a major inaccuracy."
  },
  "174": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant facts but contains a moderate factual error by incorrectly stating that BRAF-targeted therapy is not prioritized in squamous histology, despite guidelines and evidence supporting its use for actionable mutations regardless of subtype. It omits the key point that BRAF-targeted therapy is appropriate first-line treatment if the mutation is present, leading to a clinically significant omission."
  },
  "175": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate transition to EGFR TKI rather than completion of initial therapy, which is a major inaccuracy and could lead to inappropriate clinical management."
  },
  "176": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that brain MRI with contrast is still mandatory even when IV contrast is contraindicated, which contradicts the reference. While it provides relevant background and alternatives, this moderate factual error about the necessity of contrast in the setting of renal impairment warrants a score of 2."
  },
  "177": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the enzyme inhibited by aspirin and explains its role in prostaglandin synthesis and uric acid handling, but does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference; this is a minor omission in specificity."
  },
  "178": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that broad molecular profiling is still recommended in advanced squamous NSCLC to identify rare but actionable mutations, regardless of typical clinical features; instead, it incorrectly states that routine testing is not indicated except in special cases, which is a moderate factual omission."
  },
  "179": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, correctly explains the T3 classification, stage grouping, and provides relevant details without inaccuracies or omissions."
  },
  "180": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including tumor characteristics, guideline recommendations, and the nuanced use of 21-gene RT-PCR in small tumors, but it incorrectly states that testing is not strongly recommended for tumors >0.5 cm, which contradicts the reference answer and current guidelines; this represents a moderate omission/inaccuracy."
  },
  "181": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A₂ inhibitors as the most direct class, omitting the reference answer's focus on lipoxygenase inhibitors; while the mechanistic explanation is accurate for corticosteroids, it does not answer the specific question as asked, representing a moderate factual error."
  },
  "182": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that neoadjuvant therapy is justified for cT1c, cN0, HER2-positive disease, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "183": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline references and a helpful summary table, with no inaccuracies or omissions."
  },
  "184": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class as an acetylcholine release inhibitor, and provides additional accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "185": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, clearly stating that coal tar's precise molecular mechanism is unknown, while providing additional, accurate, and clinically relevant context about its antiproliferative effects; there are no inaccuracies or omissions."
  },
  "186": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key point that the molecular mechanism is unclear, but it introduces tranexamic acid and details its general antifibrinolytic mechanism, which is not specified in the reference. While the extra content is factually correct, it goes beyond the reference's strict \"unknown mechanism\" stance, and the answer does not fully align with the reference's emphasis on the lack of known cellular or molecular interaction."
  },
  "187": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies VEGF/VEGFR as the primary anti-angiogenic target and discusses relevant agents, but it introduces some confusion by focusing on ruxolitinib and other agents not directly related to the anti-angiogenic mechanism described in the question. This constitutes a minor inaccuracy in focus, but the key fact (VEGF/VEGFR) is present and clearly explained."
  },
  "188": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of transpeptidase-mediated cross-linking as the key mechanism, thoroughly explains the role of PBPs, and provides relevant, accurate clinical context with no omissions or inaccuracies."
  },
  "189": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes current guidelines, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "190": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies medium-chain triglycerides, their absorption via passive diffusion, and mentions fatty acid transport proteins (FATPs), but it does not directly reference the structural macromolecules (cellular membrane components of enterocytes) as in the reference answer, and instead focuses on transporter proteins, which is a partial but not complete match."
  },
  "191": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context, mechanism of resistance, and the role of AR splice variants, but it names AR-V7 instead of AR-V3 as the specific target, which is a moderate factual inaccuracy since the reference answer specifies AR-V3."
  },
  "192": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies tubulin as the principal pharmacologic target, thoroughly explains the clinical context, mechanism of action, and provides relevant supporting details without any inaccuracies or omissions."
  },
  "193": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "194": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, accurately describing the evidence base and standard practice, but it overemphasizes the lack of evidence for omission after mastectomy and implies it is generally not allowed, whereas the reference states omission is allowable if nodal RT is planned; this is a moderate omission."
  },
  "195": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly describing the reduction of ischemia-reperfusion injury and the role of neutrophil adhesion, but omits explicit mention of free radical scavenging, which is the specific molecular mechanism highlighted in the reference answer."
  },
  "196": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies DNA gyrase as the principal target for decatenation, whereas the reference specifies topoisomerase IV; while the explanation is detailed and mostly accurate, it misses the key fact that topoisomerase IV is the main enzyme responsible for decatenation in bacteria, resulting in a moderate factual error."
  },
  "197": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on retinoic acid’s effects on gene transcription and epithelial differentiation, omitting the reference answer’s key mechanism—antioxidant (free radical scavenging) activity—thus missing the principal molecular mechanism required."
  },
  "198": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference (binding of bile acids in the intestine, interrupting enterohepatic circulation), but its primary mechanism statement emphasizes increased hepatic conversion of cholesterol to bile acids rather than the binding itself; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "199": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating surveillance frequency is the same, whereas the reference specifies that post-radiotherapy surveillance should be more frequent than post-surgical protocols; this is a major inaccuracy."
  },
  "200": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "201": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, and contains no inaccuracies or omissions."
  },
  "202": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the need for individualized assessment and that moderate restriction does not automatically preclude surgery, but it overstates that standard therapy is \"generally considered appropriate\" without sufficient emphasis that moderate restriction may require modification or contraindicate surgery, as highlighted in the reference."
  },
  "203": {
    "score": 2.0,
    "explanation": "2: The model answer directly contradicts the reference by stating that metaplastic carcinoma is included, whereas the reference specifies it is not among the eligible subtypes; this is a moderate factual error, though the rest of the content is otherwise relevant."
  },
  "204": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that ALND is generally required if any node (including the marked one) remains positive after systemic therapy, and that SLNB alone is not sufficient in this case; it also provides relevant, up-to-date guideline references and clarifies exceptions, with no inaccuracies or omissions."
  },
  "205": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides accurate, relevant explanation, but does not specify COX-1 as the most directly responsible isoform as in the reference answer; this is a minor omission."
  },
  "206": {
    "score": 4.0,
    "explanation": "4: The model answer accurately describes the physiochemical mechanisms (reflection, scattering, absorption) by which sunscreens prevent UV penetration, covering nearly all key facts, but does not explicitly use the term \"physiochemical activity\" as the general class, which is a minor wording inaccuracy."
  },
  "207": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the necessity of confirming M0 status with brain MRI and FDG-PET/CT, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "208": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies sulfonamides as PABA analogs, explains their competitive inhibition of dihydropteroate synthase, and links this to folate and DNA synthesis inhibition, fully covering all key clinical facts in the reference answer."
  },
  "209": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug, details its mechanism as PDE3 inhibition (an enzyme interaction), and explains the downstream effects, fully covering all key clinical facts in the reference answer with accurate and relevant elaboration."
  },
  "210": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the receptor as an intracellular steroid hormone receptor of the nuclear receptor superfamily and provides accurate, relevant mechanistic detail, but does not explicitly use the term \"glucocorticoid receptor\" as in the reference, which is a minor wording inaccuracy."
  },
  "211": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the contraindication to surgery due to both N3 disease and poor lung function, and correctly identifies non-surgical therapies as preferred, with no inaccuracies or omissions."
  },
  "212": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as enzymatic catalysis (enzyme activation) and provides relevant details, but uses broader terms like \"enzyme replacement\" and \"enzyme activity\" rather than the precise term \"enzyme activation\" from the reference; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "213": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that durvalumab is not recommended in patients with EGFR exon 19 deletion or L858R mutation, which is a moderate factual error and contradicts the reference answer; while it provides rationale and cites guidelines, it misrepresents current indications, covering less than 70% of key facts."
  },
  "214": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of actionable mutations in squamous NSCLC and the importance of considering molecular testing in never/light smokers or atypical cases, but it incorrectly suggests that routine testing can be omitted in typical smokers, whereas the reference states broad profiling is still warranted and should not be omitted solely based on histology. This is a moderate omission."
  },
  "215": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant guideline-based recommendations without any inaccuracies or omissions."
  },
  "216": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating that the same surveillance schedule is appropriate, whereas the reference specifies that a more intensive schedule is required after radiotherapy; this is a major inaccuracy."
  },
  "217": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug, its mechanism, and clinical context, but the pharmacological class given (\"anticoagulant\") is less precise than \"enzyme activators\" as required by the reference; this is a moderate omission of the key classification."
  },
  "218": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the clinical scenario, identifies pyrantel pamoate as a nicotinic agonist causing spastic paralysis via persistent depolarization, but it does not mention cholinesterase inhibitors as in the reference, thus missing the specific drug class and mechanism required by the question."
  },
  "219": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and provides relevant clinical context, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference, representing a minor omission."
  },
  "220": {
    "score": 2.0,
    "explanation": "2: The model answer misunderstands the scenario—if definitive local therapy is not possible, this by definition includes surgery, which is a form of definitive local therapy. The answer introduces confusion by suggesting surgery could still be considered, missing the key clinical fact that surgery is inherently excluded in this context."
  },
  "221": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant explanations, and includes no inaccuracies or omissions."
  },
  "222": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, and provides relevant supporting guideline information without any inaccuracies or omissions."
  },
  "223": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, emphasizing zinc's role as a metalloenzyme cofactor in protein synthesis and cellular proliferation, but does not explicitly mention its \"electrolyte activity\" as in the reference; however, the mechanistic explanation is accurate and clinically relevant."
  },
  "224": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate explanation of corticosteroid action but incorrectly identifies phospholipase A2 as the directly inhibited enzyme system, rather than lipoxygenase as specified in the reference; this constitutes a moderate factual error."
  },
  "225": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate context about MET inhibitors, guidelines, and histology, and contains no inaccuracies or omissions."
  },
  "226": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly identifies the drug class, mechanism, and both relevant receptor subtypes, but does not single out 5-HT₁B as the sole direct molecular target as specified in the reference; this is a minor omission in specificity."
  },
  "227": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional detail, cites guidelines, and contains no inaccuracies or omissions."
  },
  "228": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the need for pathologic confirmation, explains the limitations of PET/CT, and correctly outlines the clinical implications; there are no inaccuracies or omissions."
  },
  "229": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that brain MRI is not mandatory for asymptomatic stage II patients, but it incorrectly implies that routine imaging is only for stage III or higher, omitting that guidelines recommend brain MRI for stage II as well. This is a moderate omission, as it underrepresents the standard recommendation for stage II."
  },
  "230": {
    "score": 2.0,
    "explanation": "2: The model answer does not mention the primary reference mechanism of free radical scavenging (antioxidant effect) and instead focuses on mucin upregulation, which is a secondary effect; this represents a moderate omission of the key fact."
  },
  "231": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that durvalumab is not recommended and provides rationale based on trial data and guidelines, but it omits the key fact that osimertinib is now preferred as consolidation therapy in this molecular subgroup, which is a significant omission."
  },
  "232": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes as the relevant class and explains their role in albendazole metabolism, but incorrectly specifies CYP3A4 (rather than the reference's CYP1A subfamily) and introduces flavin-containing monooxygenase, which is not mentioned in the reference; these constitute minor errors and inaccuracies."
  },
  "233": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough and accurate explanation of the mechanism of thrombopoietin receptor agonists (c-MPL–JAK2 complex), which is correct for current standard ITP therapy, but it does not match the reference answer (interferon alpha receptor complex) and thus misses the key fact required by the question."
  },
  "234": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and makes no omissions or inaccuracies."
  },
  "235": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed explanation of the clinical scenario and mechanism of amantadine but fails to directly identify \"ion channel interactions\" as the key pharmacological interaction, which is the central fact in the reference answer; instead, it focuses on pharmacodynamic antagonism, representing a moderate omission."
  },
  "236": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate general mechanism of corticosteroids, but does not explicitly state that the mechanism in cutaneous TB is \"unknown\" as required by the reference; instead, it classifies the action as \"non-specific immunomodulation,\" which is not fully equivalent, resulting in a minor omission."
  },
  "237": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that SVC stenting is appropriate regardless of pulmonary function and acknowledges that radiotherapy requires consideration of functional status, but it does not clearly state that external-beam radiotherapy may be inappropriate or excessively risky in cases of severely compromised pulmonary function, as emphasized in the reference. This represents a minor but clinically important omission."
  },
  "238": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the drug class (polyene antifungals) and their mechanism (binding to ergosterol/sterols to disrupt membrane integrity), but does not explicitly state \"inhibition of ergosterol synthesis\" as required by the reference; instead, it focuses on binding to ergosterol rather than inhibiting its synthesis, which is a key distinction."
  },
  "239": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that chest CT is sufficient for surveillance, and that FDG-PET/CT is not routinely indicated unless there are new symptoms or findings. Additional content is correct, guideline-based, and clinically relevant."
  },
  "240": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism as phosphodiesterase inhibition and discusses PDE4's role in anti-inflammatory effects, but it incorrectly names PDE4 instead of the reference's cGMP-specific phosphodiesterase (PDE5), and includes some confusion about drug examples, resulting in a moderate factual error."
  },
  "241": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies \"Folate synthesis inhibitor (antifolate)\" as the pharmacological class, directly matching the reference's \"Nucleic Acid Synthesis Inhibitors\" and provides accurate, clinically relevant explanation without omissions or inaccuracies."
  },
  "242": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that the recommendation assumes absence of distant metastases, and provides accurate, relevant rationale without any inaccuracies or omissions."
  },
  "243": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies fluoroquinolones and their mechanism, but incorrectly names DNA gyrase (topoisomerase II) as the most directly responsible target, whereas topoisomerase IV is the primary target in most gram-positive organisms relevant to otitis media; otherwise, the explanation is thorough and relevant."
  },
  "244": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing immunotherapy over KRAS G12C-targeted therapy in the first-line setting for high PD-L1 expression, and provides correct, relevant rationale and supporting guideline references without any inaccuracies or omissions."
  },
  "245": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies SNRIs as the class matching the described mechanism and clinical scenario, covering all key facts and providing relevant, accurate explanation; however, it does not explicitly mention \"serotonin uptake inhibitors\" as in the reference, representing a minor wording inaccuracy."
  },
  "246": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing that chemoradiation (especially sequential) is preferred over chemotherapy alone and explaining the rationale. However, it slightly overstates that chemotherapy alone is \"not considered an adequate treatment,\" whereas the reference allows both as acceptable, though chemoradiation is preferred—this is a minor wording inaccuracy."
  },
  "247": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly identifying the agent as a non-absorbed, hydrophilic/osmotic or bulk-forming agent and explaining its action in increasing stool water content and normalizing consistency. However, it emphasizes \"osmotic/hydrophilic action\" rather than specifically \"stool bulking activity,\" which is the most direct property per the reference; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "248": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies muscarinic acetylcholine receptor agonists as sharing the primary molecular target with adenosine, whereas the reference specifies adenosine receptor agonists; while the explanation of signaling pathways is accurate, the key fact (drug class) is wrong, constituting a moderate factual error."
  },
  "249": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that molecular testing is generally not routine in squamous histology but is recommended in non-smokers, and it appropriately highlights EGFR and ALK testing. However, it slightly underemphasizes the trend toward broad molecular profiling regardless of histology, and its statement on ROS1 is less definitive than current guidelines, representing a minor omission."
  },
  "250": {
    "score": 2.0,
    "explanation": "2: The model answer is thorough and well-referenced but directly contradicts the reference answer on the key clinical fact: it incorrectly states that ALND is required, whereas the reference says ALND can be omitted if only one positive node remains and adjuvant radiotherapy is planned. This is a moderate factual error, despite otherwise accurate and detailed content."
  },
  "251": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "252": {
    "score": 4.0,
    "explanation": "4: The answer correctly identifies amantadine and its primary mechanism as increasing synaptic dopamine via enhanced release and reuptake inhibition, covering most key facts. However, it omits mention of NMDA receptor antagonism, a relevant secondary mechanism noted in the reference."
  },
  "253": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly identifies the drug mechanism (PABA inhibition via dihydropteroate synthase), and provides relevant clinical context, but includes extra detail about immunomodulatory effects that, while accurate, slightly shifts focus from the reference's emphasis on folate synthesis inhibition as the mechanism. No major omissions or inaccuracies."
  },
  "254": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies Janus kinase (JAK) as the direct molecular target and provides relevant mechanistic detail, but does not specify JAK1 as the precise target as in the reference answer, representing a minor omission."
  },
  "255": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the distinction between metastatic disease and synchronous primaries, and details the criteria and implications for management, with no inaccuracies or omissions."
  },
  "256": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion of possible drugs and mechanisms, correctly emphasizing that the precise cellular mechanism is incompletely understood, but it introduces significant extraneous content and speculation about drug class, which is not required. It covers the key fact (mechanism unknown) but with unnecessary elaboration and some ambiguity, thus not fully matching the concise reference."
  },
  "257": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, addresses both modality and frequency, and provides correct, relevant extra detail without any inaccuracies or omissions."
  },
  "258": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts in the reference, accurately states that the precise mechanism is not fully understood, and provides correct, clinically relevant context about tafenoquine’s likely oxidative mechanism without any inaccuracies or omissions."
  },
  "259": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides a thorough, accurate explanation, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference answer; this is a minor omission since most NSAIDs inhibit both COX-1 and COX-2, but the reference asks for COX-1 specifically."
  },
  "260": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies fluoroquinolones and their mechanism but incorrectly names DNA gyrase (topoisomerase II) as the primary target for blocking chromosome separation, rather than topoisomerase IV, which is the key enzyme for this process in gram-negative bacteria like Neisseria gonorrhoeae. This is a moderate factual error."
  },
  "261": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that definitive thoracic chemoradiation is not appropriate, directly contradicting the reference, and omits the key fact that local thoracic therapy can be considered in selected oligoprogressive cases; while the rationale is detailed, it contains a moderate factual error and misses the nuanced clinical option supported by guidelines."
  },
  "262": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating observation alone is not acceptable, whereas the reference explicitly allows observation as an option; this is a major inaccuracy and misrepresentation of standard management."
  },
  "263": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that immediate systemic therapy is the standard initial approach for all, underemphasizing that local ablative therapy can be prioritized in select oligometastatic cases; this is a moderate omission that alters the clinical nuance of the reference answer."
  },
  "264": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies phosphodiesterase as the enzyme class but does not specify cGMP-specific phosphodiesterase, omitting the key detail from the reference answer; it also focuses on cAMP and PDE4, which is less relevant to the question's focus on cGMP."
  },
  "265": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "266": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise cellular or molecular mechanism of pentoxifylline’s vasodilatory action in vascular smooth muscle is not fully characterized, closely matching the reference. It provides additional, accurate, and relevant context about pentoxifylline’s effects, but slightly diverges by naming pentoxifylline instead of papaverine, which is the drug referenced in the stem and reference answer—this constitutes a minor inaccuracy in drug identification."
  },
  "267": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies interferons as the class with the most similar mechanism, rather than RNA replicase inhibitors as in the reference; while the mechanistic explanation is accurate for interferons, it misses the key fact that the question asks for a pharmacologic class with a similar antiviral mechanism (direct inhibition of viral genome replication), not the same host-mediated pathway."
  },
  "268": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly clarifies that management as two primaries is not based solely on curability but on strict diagnostic criteria, and provides accurate, relevant additional detail without inaccuracies or omissions."
  },
  "269": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine PET/CT and brain MRI are not recommended, and correctly describes standard follow-up with history, physical, and chest CT. Additional content is guideline-based, relevant, and free of inaccuracies."
  },
  "270": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies nintedanib and its inhibition of multiple tyrosine kinase receptors, but incorrectly states that the PDGF receptor family is the principal molecular target, whereas the reference specifies the fibroblast growth factor receptor family; this is a moderate factual error."
  },
  "271": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing that biopsy of metastatic lesions is strongly recommended but not strictly required before starting SERMs, and cites relevant guidelines. However, it slightly underplays the clinical expectation that receptor status should ideally be confirmed on metastatic tissue, as stated in the reference, making this a minor omission."
  },
  "272": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies albumin as the infused agent and explains its mechanism as increasing oncotic pressure, but it emphasizes the term \"colloid osmotic agent\" rather than \"structural macromolecule,\" which is the key class in the reference; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "273": {
    "score": 2.0,
    "explanation": "2: The model answer covers some key facts (definition of M1a, default assumption of metastasis, and standard management), but it omits the important nuance that management may presume both lesions are potentially resectable primaries in select cases, as highlighted in the reference. It overstates the default as always metastatic, missing the clinical context where curative treatment may be considered, and thus has a moderate omission."
  },
  "274": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but contains a significant inaccuracy: it incorrectly states that osimertinib is recommended as subsequent therapy if no prior EGFR TKI was given, whereas in this scenario, osimertinib would be used as first-line, not subsequent, therapy. The rest of the answer is detailed and accurate, but this error lowers the score."
  },
  "275": {
    "score": 3.0,
    "explanation": "3: The answer correctly explains corticosteroids' mechanism in reducing leukotriene-mediated inflammation but does not identify \"lipoxygenase inhibitors\" as the specific pharmacological class directly responsible, missing the key fact required by the question."
  },
  "276": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and cites relevant guidelines; there are no omissions or inaccuracies."
  },
  "277": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies prostaglandin analogs and their action on G-protein-coupled prostaglandin receptors, and provides accurate, relevant mechanistic detail. However, it does not explicitly name \"EP receptors\" (the specific prostaglandin E receptors), which is the precise molecular target referenced in the key fact."
  },
  "278": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies IL-1 signaling as the directly inhibited pathway and provides accurate, relevant mechanistic detail, but the reference specifically emphasizes \"antagonism of the interleukin-1 receptor,\" which is not explicitly stated as the direct inhibition in the model answer; this is a minor omission."
  },
  "279": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that preoperative pulmonary function assessment is mandatory, and provides relevant, accurate rationale without any omissions or inaccuracies."
  },
  "280": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies β-adrenergic agonists as the drug class, explains the mechanism (Gs protein-coupled receptors, cAMP, increased automaticity/conduction), and relates it to emergency cardiac use; however, it does not specifically mention beta2-agonists as in the reference, instead using the broader \"β-adrenergic agonists,\" which is a minor wording inaccuracy."
  },
  "281": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as ACTH (corticotropin) analog acting as a melanocortin 2 receptor agonist, which is accurate and clinically relevant, but does not explicitly use the term \"pituitary hormone receptor agonist\" as in the reference; this is a minor wording inaccuracy that does not alter the meaning."
  },
  "282": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why targeted therapy is precluded, and correctly prioritizes systemic chemotherapy (with or without immunotherapy); all additional content is factually correct and clinically relevant."
  },
  "283": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the presumed mechanism of I-131, but it does not align with the reference answer, which emphasizes that the precise cellular or molecular mechanism is unknown; thus, the model overstates current knowledge and omits the key fact that the exact cytotoxic action remains unclear."
  },
  "284": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly stating surveillance should be every 6 months for 2–3 years, but omits that a 3–6 month interval is also acceptable and may be preferred due to higher recurrence risk post-radiation; this is a moderate omission."
  },
  "285": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly identifies albendazole as the drug, its mechanism, and its induction of CYP enzymes, and explains the pharmacokinetic interaction. However, it introduces CYP3A4 (not mentioned in the reference) and does not specifically emphasize CYP1A, which is the key enzyme in the reference, representing a minor inaccuracy in focus."
  },
  "286": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the staging as IVA (though notes M1a rather than M1b, which is a minor technical difference but does not alter the clinical implication), and accurately recommends biomarker testing and brain MRI; all additional explanations are factually correct and clinically relevant."
  },
  "287": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies prostacyclin (IP) receptors as the primary target, explains the mechanism, and provides clinically relevant details without any inaccuracies or omissions."
  },
  "288": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed rationale, but it incorrectly states that chemotherapy should be prioritized in all cases of progression within 1 year, whereas guidelines allow for further endocrine therapy unless all options are exhausted or there is visceral crisis; this is a moderate factual inaccuracy."
  },
  "289": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides relevant, up-to-date guideline context, but introduces a minor nuance about withholding adjuvant therapy in the case of pathologic complete response (ypT0N0), which is not specified in the reference answer. This is a minor omission relative to the reference, so a score of 4 is appropriate."
  },
  "290": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides a correct, relevant explanation of chloroquine’s proposed mechanism, while appropriately noting that the exact molecular details are not fully understood; however, it goes beyond the reference’s minimalism, and the detailed mechanism—though widely accepted—may slightly overstate the certainty implied by \"unknown\" in the reference, constituting a minor wording inaccuracy."
  },
  "291": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), explains the mechanism, and notes both COX-1 and COX-2 inhibition, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary target as precisely as the reference answer."
  },
  "292": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting the mutual exclusivity of EGFR and ALK but overemphasizes rare co-occurrence and suggests that use of EGFR TKIs does not imply ALK negativity, which contradicts the reference's assertion that therapy selection presupposes ALK negativity; this represents a moderate factual inaccuracy."
  },
  "293": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant guidelines and evolving evidence but incorrectly states that omission of further axillary surgery can be considered with three positive SLNs, which exceeds the standard evidence-based threshold (1–2 positive nodes); this is a moderate factual error and overstates guideline support, missing the key reference fact that omission is not appropriate in this scenario."
  },
  "294": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies serotonin receptor modulation (agonism and antagonism) as the primary mechanism, covers nearly all key facts, and provides relevant clinical context; however, it introduces some ambiguity and minor inaccuracies regarding specific drugs (e.g., verapamil, melatonin agonists) that are not directly relevant to the mechanism asked, slightly detracting from precision."
  },
  "295": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that adjuvant radiotherapy is not category 1 and provides accurate rationale, but it incorrectly assigns a category 2A (uniform consensus) rather than the reference's category 2B (lower consensus), representing a minor inaccuracy in guideline classification."
  },
  "296": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining both the staging and pulmonary function contraindications, and appropriately recommends non-surgical management without any inaccuracies or omissions."
  },
  "297": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies magnesium as the agent and explains its role as a calcium antagonist, but it does not explicitly mention \"calcium chelation\" or the reduction of free extracellular calcium, which is the key mechanism in the reference answer; instead, it focuses on channel antagonism, which is related but not identical."
  },
  "298": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the medication as IVIG instead of aminobenzoate potassium, which is a moderate factual error; while it correctly states the mechanism is undefined, most content is irrelevant to the question."
  },
  "299": {
    "score": 2.0,
    "explanation": "2: The model answer covers less than 70% of the key facts, incorrectly states that erlotinib is not appropriate first-line therapy (contradicting guidelines for actionable EGFR mutations), and overemphasizes histology exclusion, which is not absolute; while it provides relevant rationale, it omits that erlotinib is recommended for sensitizing EGFR mutations regardless of histology, constituting a moderate factual error."
  },
  "300": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, correct additional details without any omissions or inaccuracies."
  },
  "301": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of reduced pulmonary function on surgical candidacy, and appropriately recommends radiotherapy/SABR as preferred alternatives; all additional content is correct and clinically relevant."
  },
  "302": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides a thorough, accurate explanation, but it does not specify the COX-2 isoform (Prostaglandin G/H Synthase 2) as in the reference answer, representing a minor omission."
  },
  "303": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate detail about patient selection and guidelines, and contains no inaccuracies or omissions."
  },
  "304": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that broad molecular profiling is still indicated in advanced squamous cell carcinoma because rare actionable mutations can occur regardless of histology; instead, it incorrectly states that profiling is generally not indicated except in select cases, which is a moderate factual error."
  },
  "305": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of valproic acid’s proposed mechanisms but does not directly state that the precise cellular or molecular mechanism remains unknown, as in the reference. It covers most key facts but slightly overcommits to mechanistic details, missing the emphasis on the uncertainty required by the question."
  },
  "306": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes both re-excision and radiotherapy as guideline-supported options, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "307": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that adjuvant chemotherapy with trastuzumab is \"not typically recommended\" and \"generally not standard\" for T1aN0 HER2+ tumors, whereas the reference clarifies that it may still be considered (category 2B) and is not strictly limited to larger tumors; this is a moderate omission."
  },
  "308": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the follow-up regimen is unchanged by adjuvant radiotherapy, omitting the key fact that more intensive surveillance (every 3–6 months for 3 years, then every 6 months for 2 years) is recommended after radiotherapy; this is a moderate factual omission, though the rest of the content is generally accurate."
  },
  "309": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for prioritizing osimertinib over durvalumab, references relevant trials, and provides correct, clinically relevant additional context without inaccuracies or omissions."
  },
  "310": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the lipid-based agent as vitamin E and accurately describes its antioxidant mechanism involving interaction with large biomolecules (membranes/lipoproteins), but it focuses specifically on vitamin E rather than the broader concept of lipid supplements (e.g., cholesterol) as in the reference; this is a minor omission in scope but otherwise clinically accurate and relevant."
  },
  "311": {
    "score": 3.0,
    "explanation": "3: The model answer covers the involvement of growth factors and gene expression but does not explicitly mention modulation of transcription factor activity, which is the primary mechanism in the reference. The explanation is accurate but misses the key molecular detail required."
  },
  "312": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, addresses prior chemoradiation, and cites guidelines; there are no inaccuracies or omissions."
  },
  "313": {
    "score": 2.0,
    "explanation": "2: The model answer identifies the adenosine A1 receptor, which is incorrect for a selective antagonist as described; the reference answer (beta-1 adrenergic receptor) is correct. The model also misinterprets the pharmacology, discussing adenosine (an agonist, not antagonist), leading to a moderate factual error and covering less than 70% of key facts."
  },
  "314": {
    "score": 2.0,
    "explanation": "2: The model answer provides several plausible mechanisms proposed in preclinical studies, but it fails to clearly state that the mechanism is unknown, which is the key fact in the reference answer; this constitutes a moderate omission."
  },
  "315": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "316": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts about the supplement's identity, its glycosaminoglycan nature, and its modulation of extracellular matrix processes, but does not explicitly use the term \"biological macromolecular activity\" as in the reference; otherwise, it is accurate and clinically relevant."
  },
  "317": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the relevant enzyme and provides a clear, accurate explanation, but does not specify the COX-2 isoform as in the reference answer, which is a minor omission."
  },
  "318": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends routine use of FDG-PET/CT and brain MRI at the initial suspicion of recurrence, whereas guidelines reserve these for confirmed recurrence or strong clinical suspicion of metastasis after chest imaging; this is a moderate factual error, though the rest of the content is accurate and relevant."
  },
  "319": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed rationale, but it overstates the recommendation to switch immediately, failing to acknowledge that both completing current therapy or switching are acceptable and should be individualized, as per the reference. This omission of the individualized approach and presentation of switching as the only recommended option constitutes a moderate factual inaccuracy."
  },
  "320": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the clinical context, the role of catecholamines, and the mechanism of reuptake inhibition, but it equivocates between norepinephrine and dopamine as the \"key\" neurotransmitter, whereas the reference answer specifies dopamine reuptake inhibition as primary. This represents a minor but meaningful inaccuracy in emphasis, lowering the score."
  },
  "321": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the mechanism of DNA alkylating agents and their effects but misidentifies azacitidine/decitabine as alkylating agents rather than nucleic acid synthesis inhibitors (they are DNA methyltransferase inhibitors), and does not directly state the class as \"nucleic acid synthesis inhibitors\" as in the reference."
  },
  "322": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies tetracyclines as the class with the described mechanism and provides accurate clinical reasoning, but it omits the broader class \"protein synthesis inhibitors\" as in the reference answer, which is a minor omission."
  },
  "323": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferon as the recombinant protein and accurately describes its immunomodulatory mechanism, but it does not explicitly use the reference term \"Biological Response Modifiers\" as the pharmacologic class, instead using \"Immunomodulator (Recombinant Interferon),\" which is related but not the precise answer required."
  },
  "324": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the IL-6 receptor as the molecular target and provides a thorough, accurate explanation of CRS and tocilizumab’s mechanism, but omits explicit mention of the alpha subunit (IL-6Rα) specified in the reference answer."
  },
  "325": {
    "score": 1.0,
    "explanation": "1: The model answer does not identify the correct transporter class (Organic Anion Transporter 3) and instead incorrectly focuses on ATP synthase, which is not an anion transporter; this is a major inaccuracy despite otherwise relevant discussion."
  },
  "326": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing that adjuvant therapy is not routinely recommended without high-risk features and listing relevant guidelines and risk factors; however, the initial statement that consideration \"does not inherently assume\" high-risk features is a minor wording inaccuracy compared to the reference, which more clearly states that high-risk features are generally presumed."
  },
  "327": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly identifying pentoxifylline and its effects on RBC deformability and blood viscosity, but it does not clearly state that the precise cellular or molecular mechanism is unknown, as required by the reference answer; instead, it provides proposed mechanisms, which is a minor but relevant omission."
  },
  "328": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, accurately stating that the precise mechanism is incompletely understood, and provides additional correct and relevant mechanistic context; however, it speculates on possible mechanisms, which, while not incorrect, slightly exceeds the reference's agnostic stance."
  },
  "329": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies inhibition of ergosterol synthesis and the ergosterol biosynthesis pathway, but incorrectly specifies the enzyme as lanosterol 14-α-demethylase (azoles) rather than squalene epoxidase (allylamines), which is the key fact in the reference answer. No unsafe statements are present, but this is a moderate factual error."
  },
  "330": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the FIP1L1-PDGFRA fusion gene as the primary molecular abnormality targeted by imatinib in this clinical context, matching the clinical scenario and providing accurate, relevant detail without any inaccuracies or omissions."
  },
  "331": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains the mechanism, but does not specify COX-2 as the primary isoform relevant to the anti-inflammatory effect, which is a minor omission."
  },
  "332": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, and contains no inaccuracies or omissions."
  },
  "333": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies tetracyclines (demeclocycline) and explains their use in SIADH, but it does not explicitly state \"protein synthesis inhibitors\" as the drug class mechanism, which is the key fact in the reference answer; otherwise, the explanation is accurate and relevant."
  },
  "334": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but equivocates on the need for systemic therapy, suggesting observation may still be reasonable despite clear evidence of progression in one nodule, which underemphasizes the clinical priority for active treatment in this context; it also introduces guideline references that do not specifically address this nuanced scenario, leading to minor inaccuracy and omission."
  },
  "335": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies selective glucocorticoid receptor modulators (SGRMs) as the class, which is a more specific subset of glucocorticoid receptor agonists, and provides accurate, relevant clinical context. However, it does not explicitly state \"glucocorticoid receptor agonists\" as in the reference, representing a minor wording inaccuracy."
  },
  "336": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts about erythropoietin receptor activation and the downstream JAK2-STAT pathway, with clear, accurate, and relevant explanations; however, it emphasizes the JAK2-STAT pathway as the \"direct\" answer rather than the receptor activation itself, which is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "337": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "338": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies GPCRs as the direct biological target, explains the clinical scenario, mechanism, and links adenosine’s action to AV nodal conduction via GPCRs, fully covering all key facts in the reference answer with relevant, accurate detail."
  },
  "339": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug, its mechanism, and its effect, but the pharmacological class given (\"antimetabolite (ribonucleotide reductase inhibitor)\") is less precise than \"nucleic acid synthesis inhibitor\" and omits the key reference terminology, covering about 70-89% of the key facts."
  },
  "340": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the clinical scenario and the drug (nitazoxanide), but incorrectly classifies the mechanism as \"nitroimidazoles\" rather than \"uncouplers,\" and provides a mechanism (PFOR inhibition) that does not match the reference's focus on uncoupling the electron transport chain; this represents a moderate factual error and incomplete alignment with the reference answer."
  },
  "341": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "342": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of corticosteroids (inhibition of phospholipase A2), but does not directly answer the question, which specifically asks for the enzyme whose inhibition reduces leukotriene synthesis (lipoxygenase). The explanation is accurate but misses the key fact required by the question."
  },
  "343": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and includes relevant guideline references without any inaccuracies or omissions."
  },
  "344": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic mediastinal lymph node evaluation, and provides relevant, guideline-based rationale without inaccuracies or omissions."
  },
  "345": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed, accurate description of the proposed mechanism of metronidazole, but it omits the key fact from the reference that the precise molecular mechanism in bacterial vaginosis is unclear; thus, it overstates current knowledge and misses a critical nuance."
  },
  "346": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant rationale and guidelines, and includes no inaccuracies or omissions; extra content is accurate and clinically pertinent."
  },
  "347": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, accurately describing the mechanism as metabolic supplementation and explaining the role of substrates/cofactors in mitochondrial energy metabolism; however, it omits the specific terminology \"biological macromolecular activity\" from the reference."
  },
  "348": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on polyene antifungals (e.g., nystatin) rather than ergosterol synthesis inhibitors, which is the reference answer. While it correctly describes the mechanism of amphotericin B and its similarity to nystatin, it does not address the class of ergosterol synthesis inhibitors, representing a moderate omission of the key fact required by the question."
  },
  "349": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of corticosteroids and the role of phospholipase A2, but it fails to directly identify \"lipoxygenase inhibitors\" as the answer, omitting the key fact that the question specifically asks for the enzyme class responsible for leukotriene production (lipoxygenase), not the upstream enzyme (phospholipase A2)."
  },
  "350": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that systemic therapy is prioritized in metastatic (stage IV) NSCLC and discusses the potential role of local therapy after systemic treatment, but it omits the reference answer’s recommendation to combine local therapy for the metastatic site with concurrent chemoradiation for locoregional disease upfront in oligometastatic cases, thus missing a key management nuance."
  },
  "351": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 as the inhibited enzyme instead of CYP2C19, which is the key fact in the reference answer. While the explanation is detailed and mostly relevant, this constitutes a moderate factual error, and the rest of the content does not compensate for the incorrect enzyme."
  },
  "352": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant detail about operability criteria and alternative treatments, and contains no inaccuracies or omissions."
  },
  "353": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing the necessity of brain MRI before systemic therapy and clarifying the conditional need for PFTs, but it slightly underemphasizes that both tests are generally considered required prerequisites per guidelines, resulting in a minor omission."
  },
  "354": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes further endocrine therapy despite recent progression, missing the key fact that progression within a year indicates endocrine resistance and warrants chemotherapy; while the rationale is guideline-based, it overlooks the specific clinical context, constituting a moderate omission."
  },
  "355": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate mechanism of how arginine and aspartate correct metabolic alkalosis, but it does not directly identify the general pharmacological action as \"biological macromolecular activity\" as in the reference; instead, it focuses on renal and metabolic effects, thus missing the key general classification."
  },
  "356": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishing between metastatic disease and second primary tumors, and outlines the appropriate treatment approach for each scenario with accurate, relevant detail and no inaccuracies or omissions."
  },
  "357": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on histamine H3 receptor antagonism rather than calcium channel interactions, omitting the key mechanism specified in the reference. While the explanation is detailed and mostly accurate for betahistine, it does not directly address the class of pharmacological interaction asked (calcium channel interactions), constituting a moderate omission."
  },
  "358": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly explaining that surgical management may be considered if both lesions are resectable, regardless of whether they are primaries or metastases, and details the distinction between synchronous primaries and metastases. However, it does not clearly state that surgical management in this setting presupposes both lesions are individually curable and should be managed as two primaries if so, as the reference answer does, and its initial \"No\" is somewhat misleading relative to the reference."
  },
  "359": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly clarifies that immunotherapy monotherapy is not appropriate but combination chemo-immunotherapy is standard, and provides relevant, accurate rationale and caveats without any inaccuracies or omissions."
  },
  "360": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed, accurate summary of pirfenidone’s proposed mechanisms but does not directly state that the precise mechanism is unknown, as required by the reference; it covers most key facts but omits the central uncertainty emphasized in the reference answer."
  },
  "361": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, correctly identifies inhibition of nucleic acid synthesis as the relevant pharmacological action, and provides accurate, clinically relevant mechanistic detail without inaccuracies or omissions."
  },
  "362": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise mechanism is not fully defined and describes the known pharmacologic action of apremilast, which is factually accurate and clinically relevant; however, it assumes the agent is apremilast rather than modified cyclosporine as in the reference, representing a minor inaccuracy in interpretation but not in the mechanism explanation itself."
  },
  "363": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant guideline-based details, and contains no inaccuracies or omissions."
  },
  "364": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, and includes no inaccuracies or omissions. It appropriately emphasizes that molecular testing is not essential, details exceptions, and highlights the importance of PD-L1 testing."
  },
  "365": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that chest CT every 3–6 months is appropriate for stage II NSCLC post-surgery without radiotherapy, whereas guidelines recommend every 6 months; it also misinterprets the flexibility in surveillance intervals, leading to a moderate factual error."
  },
  "366": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately noting that adjuvant radiotherapy is not always mandatory and that surveillance may be acceptable in select cases; it adds relevant, guideline-based detail and examples without inaccuracies or omissions."
  },
  "367": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the beta-2 adrenergic receptor as the relevant GPCR, discusses the mechanism, and clarifies the pharmacology of drugs used in PAD, with no inaccuracies or omissions."
  },
  "368": {
    "score": 3.0,
    "explanation": "3: The model answer focuses on vitamin A's role in epithelial differentiation and mucin production via nuclear receptor activation, but it omits the principal mechanism specified in the reference—antioxidant/free radical scavenging activity—thus missing the key fact required."
  },
  "369": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes systemic therapy over local intervention for an isolated, asymptomatic endobronchial obstruction, missing the key reference point that local therapy is preferred initially in the absence of disseminated disease; while the answer is detailed and safe, this represents a moderate factual error."
  },
  "370": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides relevant clinical context, but it specifies only COX-2, omitting COX-1, which is also inhibited by most oral NSAIDs; this is a minor omission."
  },
  "371": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class as a nucleic acid synthesis/function inhibitor, accurately describes clofazimine’s mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "372": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately discusses the risks of concurrent chemoradiation in poor pulmonary function, emphasizes multidisciplinary assessment, and outlines appropriate alternative strategies without any inaccuracies or omissions."
  },
  "373": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "374": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the role of COPD in risk stratification, and provides correct, relevant additional details without any inaccuracies or omissions."
  },
  "375": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts and provides accurate, relevant detail about the disease, therapy, and mechanism, but does not explicitly use the term \"biological response modification\" or \"immune modulation\" as in the reference, which is a minor wording omission."
  },
  "376": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes as the relevant class and explains the induction mechanism, but it generalizes to the entire CYP450 family (especially CYP3A4) rather than specifically mentioning CYP1A, as in the reference. This is a minor but clinically relevant omission, as CYP1A is the most pertinent isoform for benzimidazole induction."
  },
  "377": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating that omission of mediastinal nodal assessment does not invalidate adjuvant therapy, missing the key fact that accurate nodal staging is essential for appropriate indication; this is a major inaccuracy with potential clinical implications."
  },
  "378": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the increased risks and need for individualized assessment, but it contradicts the reference by stating that prior RT is not an absolute contraindication and that re-irradiation may be appropriate, whereas the reference emphasizes that prior RT is generally a contraindication and repeat RT is typically not pursued. This represents a moderate factual discrepancy."
  },
  "379": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred and radiotherapy is a secondary option, with no inaccuracies or omissions. Additional content is accurate, relevant, and well-referenced."
  },
  "380": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of metronidazole’s mechanism (DNA damage via free radicals), but the reference answer states the precise molecular target is unknown, so the model overstates current knowledge; this is a moderate factual error."
  },
  "381": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts, correctly identifies the pharmacological class (beta-lactam antibiotics/cephalosporins), explains the mechanism (enzyme inhibition), and provides relevant clinical context without inaccuracies or omissions."
  },
  "382": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, and includes relevant, correct additional details without any inaccuracies or omissions."
  },
  "383": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies carbamazepine as the culprit and discusses CYP3A4 induction, but it omits CYP2C19, which is the key enzyme specified in the reference answer, and instead focuses on CYP3A4 and CYP2C9, leading to a moderate factual omission."
  },
  "384": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that endocrine therapy recommendations require assessment for contraindications like thromboembolic risk, and that tamoxifen is contraindicated in such cases. However, it omits the specific point that aromatase inhibitors are preferred over tamoxifen in postmenopausal women with elevated thromboembolic risk."
  },
  "385": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly identifying the drug as a recombinant cytokine that modulates immune responses and explaining the mechanism in detail. However, it does not explicitly use the term \"biological response modifier,\" which is the concise drug class mechanism in the reference, representing a minor omission."
  },
  "386": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies miltefosine and broadly describes its action on membrane phospholipids/lipid receptors, but it does not specifically mention \"lysophospholipid receptors\" as the primary molecular target, missing the key reference fact. The rest of the content is accurate and relevant."
  },
  "387": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that EGFR-targeted therapy should not be started before ALK results, directly contradicting the reference answer and current guidelines; this is a major inaccuracy and could delay appropriate care."
  },
  "388": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"nonspecific\" as the mechanism and provides accurate, relevant pharmacological context, but it does not explicitly use the phrase \"unknown cellular or molecular interaction\" as in the reference, representing a minor wording inaccuracy."
  },
  "389": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that surgery remains an option for T4, N0–1 NSCLC with ipsilateral nodules, and that systemic therapy is not automatically required; additional details provided are correct and clinically relevant."
  },
  "390": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario as PNH and accurately describes eculizumab's mechanism (C5 inhibition), but it fails to name C3, the specific complement protein targeted as per the reference answer, thus missing the key fact required."
  },
  "391": {
    "score": 4.0,
    "explanation": "4: The model answer accurately describes the known enzymatic action of exogenous lactase and acknowledges that the precise molecular details are not fully characterized, matching the reference's emphasis on unknown mechanisms; however, it provides more mechanistic detail than the reference, which is acceptable, but the answer could be slightly more concise."
  },
  "392": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that the precise mechanism of action against hepatic trematodes is not fully understood, covering the key fact, but it incorrectly identifies the drug as nitazoxanide rather than emetine hydrochloride, which is a moderate factual error."
  },
  "393": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough explanation of the clinical scenario and correctly identifies beta-lactam antibiotics as the drug class, but it does not explicitly state \"enzyme inhibitors\" as required by the reference answer, missing the key fact that the primary mechanism is enzyme inhibition."
  },
  "394": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacological class and mechanism, and provides relevant, accurate additional details without any errors or omissions."
  },
  "395": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the role of adjuvant radiation and surveillance, and adds relevant, correct detail without any inaccuracies or omissions."
  },
  "396": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on zinc’s antiviral effects (inhibition of viral replication and adhesion) but omits the key reference fact—acid-base activity (alteration of local pH)—as the primary mechanism, which is a moderate omission. The rest of the content is relevant and accurate."
  },
  "397": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough clinical summary and correctly describes the pharmacology of phenothiazines, but it incorrectly identifies dopamine D2 antagonism as the most relevant mechanism, whereas the reference answer specifies adrenergic alpha-antagonism. This represents a moderate factual error regarding the mechanism most pertinent to the clinical context."
  },
  "398": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides relevant, accurate explanations, but it specifies \"every 6 months for the first 2 years, then annually,\" which is slightly less frequent than the reference's \"every 3–6 months for the first 3 years,\" representing a minor wording inaccuracy that does not alter the main clinical message."
  },
  "399": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and mechanism but does not use the specific pharmacologic class \"enzyme activators\" as in the reference; instead, it uses \"procoagulant agents,\" which is accurate but less precise per the reference. All key facts are covered, but the main terminology differs."
  },
  "400": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT and brain MRI are not recommended, and that surveillance should be limited to chest CT. Additional content is correct, guideline-based, and clinically relevant, with no inaccuracies or omissions."
  },
  "401": {
    "score": 2.0,
    "explanation": "2: The model answer provides plausible mechanisms for omega-3 fatty acids' anti-inflammatory effects but fails to state that the precise cellular or molecular mechanism in Sjögren's syndrome is unclear, which is the key fact in the reference answer; this is a moderate omission."
  },
  "402": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly states that surveillance imaging (chest CT with H&P) is recommended every 6 months for the first 2–3 years and that the schedule is the same after surgery or definitive chemoradiation. However, it omits the lower bound of the 3–6 month interval (only mentions every 6 months), which is a minor omission."
  },
  "403": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "404": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the timing of dabrafenib plus trametinib initiation, and provides relevant, guideline-based context without any inaccuracies or omissions."
  },
  "405": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies rifamycins as the drug class, accurately describes their mechanism, and provides relevant, factually correct additional information without any inaccuracies or omissions."
  },
  "406": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference by stating that treating both lesions as separate primaries does not implicitly require both to be potentially curable, missing the key clinical fact that this approach is only considered when both are potentially curable; while the explanation is detailed and accurate in staging, it omits the central requirement for curability."
  },
  "407": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies iron deficiency anemia, explains the role of iron in heme synthesis, and details the cellular process enhanced by therapy. However, it omits explicit mention of \"iron transport and utilization\" and the role of electrolyte activity, which are key phrases in the reference answer, representing a minor omission."
  },
  "408": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the clinical scenario and the mechanism of action of benzimidazoles, but it does not directly state \"enzyme inhibitors\" as the general pharmacological class, which is the key fact in the reference answer."
  },
  "409": {
    "score": 3.0,
    "explanation": "3: The model answer omits the need for a core biopsy of the breast even when imaging is negative, which is a key fact in the reference answer; otherwise, it is accurate and provides relevant rationale."
  },
  "410": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need for urgent stenting in severe/life-threatening SVC syndrome and the appropriateness of chemoradiation in milder cases, but introduces a symptom-severity-based algorithm not present in the reference, which could be misleading since the reference prioritizes stenting for all symptomatic SVC obstruction. This represents a moderate omission and potential inaccuracy regarding initial management."
  },
  "411": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and notes inhibition of both COX-1 and COX-2, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary relevant isoenzyme, which is a minor omission."
  },
  "412": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the appropriateness of fam-trastuzumab deruxtecan for HER2-mutant NSCLC regardless of histology, but incorrectly states that first-line use is not established or recommended, whereas the reference answer supports first-line use in this setting; this constitutes a moderate omission."
  },
  "413": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the indication for brain MRI in stage II NSCLC, the rationale for non-contrast MRI in renal dysfunction, and the importance of brain imaging for staging; all additional content is accurate and clinically relevant."
  },
  "414": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of ROS1 rearrangements in squamous histology and the importance of verifying pathology, but it incorrectly states that confirmation of non-squamous histology is not required, which contradicts the reference's emphasis on histologic confirmation due to the rarity and testing recommendations. This represents a moderate factual inaccuracy."
  },
  "415": {
    "score": 4.0,
    "explanation": "4: The answer correctly identifies opioid antitussives and μ-opioid receptor agonism as the key mechanism, matching the reference. However, it introduces dextromethorphan, which is not a full opioid agonist and acts mainly via NMDA and sigma-1 receptors, making this extra detail slightly inaccurate for the specific scenario, resulting in a minor wording inaccuracy."
  },
  "416": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the diagnosis, mechanism, and therapy, but does not use the specific pharmacological class \"enzyme activators\" as in the reference answer, instead describing it as \"coagulation factor replacement\" or \"procoagulant,\" which is less precise for the question asked."
  },
  "417": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies muscarinic acetylcholine receptors as the molecular target and adds the clinically relevant detail of the M3 subtype, but the reference answer only requires the general class; this is a minor wording difference, not a substantive error."
  },
  "418": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine brain MRI is not indicated, and appropriately discusses exceptions and relevant guidelines without inaccuracies or omissions."
  },
  "419": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as RNA polymerase inhibition and provides accurate, relevant detail, but does not use the broader class term \"Nucleic Acid Synthesis Inhibitors\" as in the reference; \"RNA polymerase inhibitors\" is a more specific subclass, representing a minor wording inaccuracy."
  },
  "420": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the therapy as coagulation factor replacement and provides relevant mechanistic details, but it does not use the general pharmacological class \"enzyme activators\" as specified in the reference, omitting the key classification term required by the question."
  },
  "421": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies CD19 as the target, explains the distinction between CD19 and CD20, and provides relevant clinical context without inaccuracies or omissions."
  },
  "422": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT is not appropriate, details standard surveillance, and correctly notes PET/CT is reserved for suspected recurrence. Additional content is factually correct and clinically relevant."
  },
  "423": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizes the importance of re-biopsy to confirm hormone receptor status, and notes that original status can be used if biopsy is not feasible; however, it slightly overstates guideline flexibility compared to the reference, which more strongly recommends confirmation at recurrence."
  },
  "424": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on anticholinergic agents and first-generation antihistamines, which is a different mechanism from the serotonin antagonists specified in the reference; it omits the key fact that serotonin antagonists (e.g., ondansetron) are the relevant class, constituting a moderate omission."
  },
  "425": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferons and their immunomodulatory mechanism, but does not explicitly use the term \"biological response modifiers,\" which is the most accurate pharmacological class per the reference; otherwise, it covers most key facts with minor terminology mismatch."
  },
  "426": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the molecular target as IL-4Rα, which is the direct target of dupilumab, and explains its role in blocking both IL-4 and IL-13 signaling. However, the reference specifically asks for the cytokine directly antagonized (IL-13), not the receptor, so there is a minor wording inaccuracy."
  },
  "427": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug and its immunomodulatory mechanism but does not explicitly use the term \"immunologic adjuvant,\" which is the key fact in the reference answer; it covers the mechanism in detail but misses the precise pharmacologic class terminology."
  },
  "428": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains current guidelines, and provides relevant references; there are no inaccuracies or omissions."
  },
  "429": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing C5 inhibition, MAC blockade, and the reduction of complement-mediated intestinal protein loss, with additional correct and relevant mechanistic detail."
  },
  "430": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that moderate renal insufficiency affects regimen choice and may require dose adjustment or avoidance of certain agents, but slightly overstates the impact by implying the patient is not an ideal candidate for standard therapy, rather than clarifying that systemic therapy remains indicated with modifications. No unsafe statements are present."
  },
  "431": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for preferring SBRT over surgery in patients with significant PFT impairment, and provides relevant, guideline-based context without inaccuracies or omissions."
  },
  "432": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "433": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes bismuth’s barrier-forming action but omits the key reference point of acid-base activity and pH modulation as the primary mechanism, focusing instead on physical protection; it covers most but not all key facts."
  },
  "434": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing immediate local management for bone lesions at high risk of fracture, and correctly sequencing systemic ALK-targeted therapy after stabilization. Additional explanations are accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "435": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of action (inhibition of osteoclast-mediated bone resorption), and provides additional correct and relevant molecular detail without any inaccuracies or omissions."
  },
  "436": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not recommended, cites relevant guidelines, and correctly notes brain imaging is reserved for symptomatic patients; there are no inaccuracies or omissions."
  },
  "437": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies that the mechanism of action is not fully understood, discusses relevant agents, and ultimately provides a clinically accurate and relevant explanation matching the reference answer with no inaccuracies or omissions."
  },
  "438": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, including the current standard of care, the role and timing of targeted therapies, and relevant guideline recommendations, with no inaccuracies or omissions."
  },
  "439": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that observation is not appropriate, directly contradicting the reference answer, which allows observation in select cases without active recurrence. While the model provides relevant rationale and discusses treatment options, it omits the key fact that observation can be considered, constituting a moderate factual error."
  },
  "440": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes mast cell stabilization and inhibition of calcium influx as the direct mechanism, but it does not mention H1 receptor antagonism, which is the reference answer's key fact; thus, it covers about 70-89% of the required information."
  },
  "441": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switch to osimertinib, omitting the key fact that current therapy should be completed first; this is a major inaccuracy despite otherwise relevant content."
  },
  "442": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of increased cardiac contractility and renal perfusion via Gs-coupled receptor activation, but incorrectly identifies the pharmacological class as β1-adrenergic agonists rather than dopamine agonists, which is a moderate factual error."
  },
  "443": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts about glucocorticoids' anti-inflammatory mechanism but incorrectly identifies \"phospholipase A2 inhibitors\" as the best class, rather than \"lipoxygenase inhibitors\" as specified in the reference; this is a moderate factual error."
  },
  "444": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing re-resection over radiation, provides correct rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "445": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies Fc receptor blockade as the key immunological mechanism, which is the primary and clinically relevant effect of IVIG in this context; while the reference mentions antigen neutralization, Fc receptor blockade is the more accurate and accepted mechanism in autoimmune hemolytic anemia, with no inaccuracies or omissions present."
  },
  "446": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending continued HER2-targeted therapy after progression on multiple prior lines, which is not clinically indicated per the reference; this is a major inaccuracy that could lead to inappropriate treatment."
  },
  "447": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the exact mechanism is unknown and correctly describes the drug’s lack of GABA receptor binding, but it goes beyond the reference by detailing the proposed α2δ subunit mechanism, which, while accurate, is not definitively established and thus slightly overstates current scientific certainty. No unsafe statements are present, but the answer does not strictly adhere to the reference’s emphasis on the mechanism being unknown."
  },
  "448": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference (cholinesterase inhibitors, increased acetylcholine, stimulation of detrusor contraction), but introduces direct muscarinic agonists (bethanechol) as an alternative, which, while correct and clinically relevant, slightly shifts focus from the reference's emphasis on cholinesterase inhibitors. No major omissions or inaccuracies are present."
  },
  "449": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "450": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies competitive inhibition as the class of enzymatic inhibition, explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "451": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the rarity but importance of actionable mutations in squamous NSCLC, and correctly supports broad molecular profiling per guidelines; all additional content is clinically relevant and factually correct."
  },
  "452": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies dantrolene, its mechanism, and the clinical scenario, but it does not name \"calcium channel antagonists\" as the pharmacological class most closely related to the mechanism, which is the key fact in the reference answer."
  },
  "453": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and discusses relevant drug classes, but ultimately selects \"alpha-2 adrenergic receptor\" rather than the reference answer \"adrenergic beta2-agonist,\" missing the key fact that beta2-agonists increase aqueous outflow; otherwise, the explanation is thorough and accurate."
  },
  "454": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, details guideline recommendations, and appropriately notes rare exceptions, with no inaccuracies or omissions."
  },
  "455": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phospholipase A2 as the enzyme class inhibited by glucocorticoids to reduce leukotriene synthesis, and provides accurate, clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "456": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phosphodiesterase 5 (PDE5) as the molecular target responsible for cGMP degradation, fully aligns with the reference answer, and provides accurate, relevant explanation without errors or omissions."
  },
  "457": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies microtubules as the primary structure targeted and explains the mechanism, but does not explicitly name \"tubulin\" as the direct molecular target, which is a minor omission compared to the reference answer."
  },
  "458": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the agent as \"keratolytic\" and explains its mechanism, but it does not use the required mechanistic class term \"physiochemical activity\" from the reference answer, which is a key fact. The explanation is otherwise accurate and relevant."
  },
  "459": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly identifies GnRH antagonists as the class, and accurately explains the mechanism and clinical effect. The mention of oral GnRH agonists as a possible answer is a minor inaccuracy, as only antagonists are considered novel oral therapies, but this does not alter the overall meaning."
  },
  "460": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and notes that most NSAIDs inhibit both COX-1 and COX-2, but does not specifically name \"Prostaglandin G/H Synthase 1 (COX-1)\" as in the reference; this is a minor omission."
  },
  "461": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of HMG-CoA reductase inhibition, and provides additional correct and clinically relevant details about LDL receptor upregulation and LDL clearance, with no inaccuracies or omissions."
  },
  "462": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the molecular process (TTR mRNA degradation via RNAi), and provides correct, relevant mechanistic and clinical context without any inaccuracies or omissions."
  },
  "463": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred if feasible, but radiotherapy is appropriate when surgery is not possible due to medical, technical, or patient factors; all additional content is accurate and clinically relevant."
  },
  "464": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the key pharmacological property as antioxidant (free radical scavenging) activity via glutathione replenishment, and links this to reduced oxidative stress and organ damage in amyloidosis. However, it does not explicitly use the term \"free radical scavenging,\" which is the precise property referenced in the standard answer, representing a minor wording inaccuracy."
  },
  "465": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on the PI3K/Akt/mTOR pathway and adenosine A2A receptors, which are not the primary molecular targets of miltefosine in Leishmania; it omits the key fact that lysophospholipid receptor interactions are central to the drug's mechanism, resulting in a moderate factual error and missing the main reference point."
  },
  "466": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies COX-2 (prostaglandin-endoperoxide synthase) as a direct target and explains aspirin’s mechanism, but it does not specifically single out COX-2 as the most relevant isoform for the anti-inflammatory effect, instead listing both COX-1 and COX-2. This is a minor inaccuracy in wording but does not alter the clinical meaning."
  },
  "467": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism and class (β-lactam antibiotics) but does not explicitly state \"enzyme inhibitors\" as required by the reference answer, omitting the key fact that the primary mechanism is enzyme inhibition."
  },
  "468": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cytochrome P450 enzymes as the relevant class and provides accurate, relevant context, but does not specify CYP1A as in the reference answer, representing a minor omission."
  },
  "469": {
    "score": 3.0,
    "explanation": "3: The model answer correctly emphasizes the appropriateness of switching to crizotinib upon discovery of an ALK rearrangement and provides rationale, but it omits that either completing current therapy or switching are both acceptable options per guidelines; it presents switching as the only standard, missing the nuance of individualized clinical judgment."
  },
  "470": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclobenzaprine and provides a detailed, accurate summary of its proposed mechanism, but it does not explicitly state that the precise molecular mechanism is unknown, as required by the reference answer; instead, it presents the leading hypothesis as fact, omitting the key point of uncertainty."
  },
  "471": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishes surveillance recommendations by treatment modality, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "472": {
    "score": 4.0,
    "explanation": "4: Thorough explanation of the clinical scenario, mechanism, and drug, but the final pharmacologic class given (\"RNA polymerase inhibitor\" or \"inhibitor of bacterial RNA synthesis\") is less precise than \"nucleic acid synthesis inhibitor\" as in the reference; this is a minor wording inaccuracy."
  },
  "473": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the preference for re-resection and the consideration of adjuvant radiotherapy, but incorrectly suggests that surveillance alone may be reasonable in select patients, which is not supported by guidelines for R1 margins; this represents a moderate omission."
  },
  "474": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 as the key pathway, whereas the reference specifies CYP1A inducers; while the clinical reasoning and explanation are otherwise thorough and relevant, this represents a moderate factual error regarding the specific enzyme involved."
  },
  "475": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes systemic therapy as preferred, explains the risks of re-irradiation, and notes that repeat radiotherapy is not an absolute indication but may be considered in select cases; all additional details are correct and clinically relevant."
  },
  "476": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that brain MRI is not routinely indicated but incorrectly suggests that FDG-PET/CT may be performed immediately for any new asymptomatic abnormality, whereas standard practice is to reserve advanced imaging for suspicious findings, not all new abnormalities. This overstates the indication for PET/CT, representing a moderate factual inaccuracy."
  },
  "477": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "478": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies serotonin reuptake inhibition as the key mechanism, provides accurate context, and mentions both SSRIs and SNRIs, but introduces norepinephrine reuptake inhibition, which is not specified in the reference and slightly broadens the answer; otherwise, all key facts are present and there are no clinically significant errors."
  },
  "479": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies beta-lactam antibiotics as the pharmacological class and accurately describes their mechanism, which aligns with the reference answer's \"enzyme inhibitors.\" However, it does not explicitly use the broader term \"enzyme inhibitors,\" representing a minor wording inaccuracy."
  },
  "480": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies neutralization of pathogenic autoantibodies as the principal mechanism, and provides accurate, relevant elaboration without inaccuracies or omissions."
  },
  "481": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the risks of ceritinib in hepatic impairment, and appropriately recommends alternative ALK inhibitors, with no inaccuracies or omissions."
  },
  "482": {
    "score": 3.0,
    "explanation": "3: The model answer provides a logical, stepwise reasoning and correctly identifies that the direct target is an amino acid, but incorrectly concludes glycine instead of asparagine, missing the key fact from the reference answer. The rest of the content is relevant and not unsafe, but the main factual error limits the score."
  },
  "483": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the receptor (GABA B), explains the clinical context, and provides accurate, relevant additional information without any inaccuracies or omissions."
  },
  "484": {
    "score": 3.0,
    "explanation": "3: Identifies the correct general class (sympathomimetic amine/stimulant anorexiant) and mechanism (increased norepinephrine in hypothalamus), but incorrectly emphasizes beta-adrenergic rather than alpha-adrenergic receptor activation, omitting the key reference detail; otherwise, the explanation is relevant and not unsafe."
  },
  "485": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that annual imaging is recommended in years 4 and 5, whereas guidelines support every six months; this is a moderate factual error, though the rest of the content is accurate and relevant."
  },
  "486": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism and clinical effect of PDE3 inhibitors like cilostazol, but it does not match the reference answer, which specifies adrenergic beta-agonists as the intended class. Thus, only about 70-89% of key facts are covered, with a moderate omission regarding the pharmacological class asked."
  },
  "487": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the class as antifibrinolytic agents (lysine analogues), accurately describes their mechanism as plasmin inhibition via lysine site binding, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "488": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of corticosteroids inhibiting phospholipase A2, but it does not identify lipoxygenase as the enzyme class directly responsible for leukotriene synthesis, as required by the question; thus, it misses the key fact asked."
  },
  "489": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for chemoradiation regardless of prior chemotherapy, and provides relevant, guideline-based context without inaccuracies or omissions."
  },
  "490": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies non-contrast chest CT as the appropriate modality and provides a guideline-based surveillance interval (every 6 months), but omits the option of a 3–6 month interval and does not mention clinical examination as part of surveillance, which is a minor omission."
  },
  "491": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine PET/CT or brain MRI is not indicated, details standard surveillance, and provides correct, relevant guideline-based explanations without omissions or inaccuracies."
  },
  "492": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of excluding distant metastases with FDG-PET/CT and brain MRI, and provides correct, relevant elaboration without any inaccuracies or omissions."
  },
  "493": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that contralateral nodules should be managed as intrapulmonary metastases by default, missing the key reference point that, in the absence of nodal involvement and with both lesions resectable, they are managed as synchronous primaries; this is a moderate factual error, though the answer is otherwise detailed and not unsafe."
  },
  "494": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies carbohydrates (specifically glucose) as the macromolecule replenished and explains the mechanism, but it omits explicit mention of glycogen (the storage form), which is a key detail in the reference answer."
  },
  "495": {
    "score": 3.0,
    "explanation": "3: The model answer emphasizes antimicrobial effects and silver ion activity, covering the acidification aspect only as a secondary point, thus missing the primary mechanism of acid-base activity as specified in the reference; overall, it addresses about 70-89% of key facts."
  },
  "496": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies pellagra, niacin deficiency, the role of NAD⁺/NADP⁺ as enzyme cofactors, and the concept of cofactor replacement, but it does not explicitly use the term \"enzyme activators\" as the pharmacological class, which is the key fact in the reference answer."
  },
  "497": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the downstream ISGF3 complex and accurately explains the signaling pathway, but it omits the essential fact that the interferon alpha receptor complex is the direct mediator of the drug’s effect, as required by the question; this is a moderate omission."
  },
  "498": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as nucleoside/nucleotide analogs (RNA polymerase inhibitors) and provides accurate, relevant mechanistic detail, but does not explicitly use the broader term \"enzyme inhibitors\" as in the reference; this is a minor wording inaccuracy."
  },
  "499": {
    "score": 3.0,
    "explanation": "3: The answer correctly explains the role of COX enzymes and the anti-inflammatory mechanism of NSAIDs, but incorrectly identifies COX-2 as the primary target, whereas the reference specifies COX-1; this is a minor but clinically relevant inaccuracy."
  },
  "500": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizes the importance of brain MRI prior to therapy, and provides relevant, up-to-date context about ALK inhibitor selection. However, it slightly downplays the necessity of CNS assessment before starting crizotinib, which is a minor omission compared to the reference answer’s stronger stance."
  },
  "501": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies hyperbaric oxygen therapy and details its effects on tissue oxygenation, neutrophil function, and ROS production, but it does not mention the primary mechanism of free radical scavenging activity as stated in the reference answer, instead focusing on ROS generation, which is related but not identical."
  },
  "502": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately affirms the need for broad molecular profiling, addresses the relevance of additional driver mutations, and provides correct, clinically relevant rationale without any inaccuracies or omissions."
  },
  "503": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate discontinuation of the current regimen and initiation of ROS1-targeted therapy, which is not standard practice and could be potentially unsafe; this constitutes a major inaccuracy."
  },
  "504": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and explains the immunological rationale, but incorrectly names CCR7 instead of CXCR4 as the molecular target, which is a moderate factual error; otherwise, the explanation is relevant and accurate."
  },
  "505": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that palliative chemotherapy can be considered for both symptomatic and asymptomatic patients, and provides additional relevant, correct context without inaccuracies or omissions."
  },
  "506": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class, mechanism, and receptor subtype (SSTR2) but omits SSTR5, which is the primary molecular target for GH suppression in this context; this is a moderate factual omission."
  },
  "507": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies aminoglycosides and accurately describes their mechanism, but it does not directly state the broader pharmacological class \"protein synthesis inhibitors\" as required by the question, omitting a key fact."
  },
  "508": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for pathological confirmation and pulmonary function testing, and provides additional relevant, correct rationale without any inaccuracies or omissions."
  },
  "509": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the pharmacological class as protein synthesis inhibitors, and provides relevant, accurate additional detail about tetracyclines without any inaccuracies or omissions."
  },
  "510": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PPAR and FXR agonism as the mechanism, omitting the key fact that the agent is a thyroid hormone receptor agonist; while the general nuclear receptor mechanism is described, the specific receptor is wrong, constituting a moderate factual error."
  },
  "511": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the acidification and ammonia trapping mechanism, but omits the key fact that the primary pharmacologic property is the drug's osmotic activity, as specified in the reference answer. The explanation is accurate but does not directly address the property asked for."
  },
  "512": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "513": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanistic category as enzyme inhibition and explains the clinical context, but it does not explicitly use the broader term \"biological macromolecular activity\" as in the reference, thus missing the key fact required by the question."
  },
  "514": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts, correctly identifying pentoxifylline and its proposed mechanisms (phosphodiesterase inhibition, increased cAMP, improved microcirculation, reduced cytokine production), but it does not clearly state that the precise molecular mechanism in cerebral malaria is unknown, as emphasized in the reference; instead, it presents plausible mechanisms as established, which is a minor but relevant omission."
  },
  "515": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, mechanism of action, and specifies \"dihydrofolate reductase inhibitors,\" which is a precise subclass of folic acid metabolism inhibitors; however, it omits the broader drug class \"folic acid metabolism inhibitors\" as requested in the reference, representing a minor omission."
  },
  "516": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly distinguishes between synchronous primaries and intrapulmonary metastases, explains the impact on staging and treatment, and provides additional relevant detail without inaccuracies or omissions."
  },
  "517": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies nintedanib and its inhibition of PDGFR, FGF, and VEGF receptors, but it omits CSF1R, the specific molecular target highlighted in the reference as significantly contributing to the antifibrotic effect. This is a moderate omission, as the reference answer focuses on CSF1R rather than PDGFR."
  },
  "518": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies CYP3A4 inhibition of ergot alkaloid metabolism as the mechanism, and provides additional accurate, clinically relevant detail without inaccuracies or omissions."
  },
  "519": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the standard guideline, highlights the exception for immunosuppressed patients, and clearly states that individualized follow-up may be warranted; there are no inaccuracies or omissions."
  },
  "520": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details staging implications based on nodule location, and clearly explains management changes. All additional content is correct, clinically relevant, and enhances clarity without introducing errors or omissions."
  },
  "521": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies nintedanib and lists all three relevant receptors it inhibits, but incorrectly selects PDGFR as the \"central\" receptor, whereas the reference specifies VEGFR. The rest of the content is accurate and relevant, but this moderate factual error prevents a higher score."
  },
  "522": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that ALK inhibitor therapy can be started based on a confirmed ALK rearrangement without waiting for broad profiling, and provides additional correct and relevant context without any inaccuracies or omissions."
  },
  "523": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, including the requirement for absence of distant metastases, the rationale for local-regional control, and the shift to systemic therapy if metastases are present; all additional explanations are accurate and clinically relevant."
  },
  "524": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that adjuvant endocrine therapy is reasonable for tumors ≤0.5 cm, and provides correct, relevant guideline-based rationale without inaccuracies or omissions."
  },
  "525": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and makes no unsafe or incorrect statements or omissions."
  },
  "526": {
    "score": 4.0,
    "explanation": "4: The answer covers nearly all key facts, correctly identifies the diagnosis, agent, and its physiochemical/cytostatic effects, but overemphasizes the cytostatic mechanism and antifungal action rather than focusing solely on physiochemical alteration as the primary mechanism per the reference. No clinically unsafe statements are present."
  },
  "527": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies P-glycoprotein (MDR1/ABCB1) as the directly inhibited transporter, whereas the reference specifies MATE2-K; while the explanation is detailed, this represents a moderate factual error and covers only part of the key facts."
  },
  "528": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed, accurate summary of the proposed mechanism of metronidazole but does not explicitly state that the mechanism is \"unknown\" or \"not fully understood\" as required by the reference; instead, it describes the hypothesized mechanism, thus covering most but not all key facts."
  },
  "529": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise cellular or molecular mechanism is not fully established, matching the reference, but includes additional mechanistic speculation that, while accurate and relevant, slightly exceeds the reference's strict \"unknown\" stance; no clinically significant errors or omissions are present."
  },
  "530": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the direct mechanism (restoration of lysosomal hydrolase activity), and provides clinically relevant elaboration without inaccuracies or omissions."
  },
  "531": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanations, and contains no inaccuracies or omissions."
  },
  "532": {
    "score": 4.0,
    "explanation": "4: The model answer covers the key fact that primaquine’s precise mechanism is not fully understood, and correctly notes its hypothesized actions (oxidative stress, mitochondrial disruption), but includes mechanistic details (ROS, mitochondrial electron transport) not present in the reference, which could be seen as minor over-speculation; otherwise, it is accurate and clinically relevant."
  },
  "533": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the relevant enzyme and drug class, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "534": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the appropriateness of broad molecular profiling for both adenocarcinoma and large cell histology, the need for re-biopsy or plasma-based testing if tissue is insufficient, and the rationale for comprehensive testing; all additional content is accurate and clinically relevant."
  },
  "535": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on cell surface GPCRs and nuclear receptors, omitting the key fact that the therapeutic impact on bone strength is ultimately mediated by structural macromolecules (collagen in the bone matrix), as stated in the reference. While the pharmacologic target is described, the answer does not address the most direct molecular target responsible for improved bone strength, resulting in a moderate omission."
  },
  "536": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed mechanism of povidone-iodine's general antiseptic action but does not emphasize that the specific cellular or molecular interaction with cutaneous parasites is unknown, as required by the reference. It covers the general mechanism but overstates the certainty regarding antiparasitic action, missing the key point of scientific uncertainty."
  },
  "537": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies aminoglycosides as the pharmacological class and explains their mechanism, but does not explicitly state the broader class \"protein synthesis inhibitors\" as in the reference; this is a minor omission."
  },
  "538": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the downstream signaling (ISGF3 complex) but omits the primary mediator specified in the question—the interferon alpha receptor complex. While mechanistically accurate, it does not directly answer the question as asked, missing a key fact."
  },
  "539": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on phospholipase A2 inhibition by corticosteroids, omitting the reference answer’s key fact that the question specifically asks about lipoxygenase inhibition and leukotriene synthesis; thus, it misses the direct enzyme class (lipoxygenase) relevant to the question."
  },
  "540": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the distinction between finding a BRAF V600E mutation and having completed broad molecular profiling, and provides relevant, guideline-based context without inaccuracies or omissions."
  },
  "541": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that initial surgery is preferred, whereas concurrent chemoradiation is generally prioritized for T4 disease even if technically resectable; this is a moderate factual error, though the rest of the content is accurate and relevant."
  },
  "542": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the clinical scenario, mechanism, and cites \"immunomodulator\" as the drug class, which is accurate and closely related to \"biological response modifiers.\" However, it does not explicitly use the reference term \"biological response modifiers,\" representing a minor wording inaccuracy."
  },
  "543": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism (ATP synthase inhibitor) and provides accurate, relevant details, but does not explicitly use the broader term \"enzyme inhibitor\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "544": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant guideline-based context, and provides accurate, clinically pertinent explanations without any inaccuracies or omissions."
  },
  "545": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "546": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on AMPK activation as the main property, which is not the specific mechanism referenced in the question; it only briefly mentions chelation as a secondary effect. The key fact—iron chelating activity—is not clearly identified as the primary pharmacological property, representing a moderate omission."
  },
  "547": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that adjuvant olaparib is not appropriate due to the patient's eGFR being below recommended thresholds, referencing trial exclusions and guidelines. However, it introduces some ambiguity by suggesting dose reduction for moderate impairment (30–59 mL/min) and possible re-evaluation if renal function improves, which could be misinterpreted since the reference answer is more definitive about contraindication at eGFR <40."
  },
  "548": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the role of EGFR TKIs and the need for radiotherapy in unstable patients, but it incorrectly prioritizes EGFR-targeted therapy over palliative radiotherapy in the context of diffuse brain metastases, which is a clinically significant omission compared to the reference answer."
  },
  "549": {
    "score": 0.0,
    "explanation": "0: The model answer directly contradicts the reference by recommending immediate switch to TRK inhibitor, whereas the reference states this is not standard practice; this is a major inaccuracy with potential clinical implications."
  },
  "550": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that surveillance frequency is the same after radiotherapy and surgery, directly contradicting the reference, which specifies more intensive imaging (every 3–6 months) after radiotherapy. This is a major factual inaccuracy."
  },
  "551": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, including the distinction between metastatic disease and synchronous primaries, the importance of pathology/molecular evaluation, and management implications. However, it slightly overemphasizes defaulting to metastatic management and does not clearly state that if both lesions are potentially curable, they should be managed as two primaries, as per the reference."
  },
  "552": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies thioredoxin reductase as the target and explains its role in redox balance, but does not specify the mitochondrial isoform (thioredoxin reductase 2) as in the reference answer, representing a minor omission."
  },
  "553": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly describes the mechanism as competitive antagonism, whereas hexamethonium is a noncompetitive antagonist at nicotinic receptors; otherwise, it covers most key facts and contains no unsafe statements."
  },
  "554": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant details about PFT thresholds and perioperative risks, and accurately prioritizes alternative therapies without any inaccuracies or omissions."
  },
  "555": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the IL-6R/gp130 complex instead of the interferon alpha receptor complex, which is the key fact. While the explanation is detailed, it is based on an incorrect premise, constituting a moderate factual error and covering less than 70% of the key facts."
  },
  "556": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the therapy as a thrombopoietin receptor agonist (TPO receptor/c-Mpl), rather than interferon alpha, and thus names the wrong molecular complex; while the mechanistic explanation is accurate for TPO agonists, it misses the key fact that the therapy in this scenario is interferon alpha, whose effects are mediated by the interferon alpha receptor complex."
  },
  "557": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts in the reference, accurately explaining that platinum-based chemotherapy is preferred over EGFR-targeted therapy in pure squamous cell carcinoma with EGFR S768I mutation, and provides relevant, correct additional context without inaccuracies or omissions."
  },
  "558": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of evidence for RET inhibitors in squamous NSCLC, references guidelines, and provides correct, relevant additional details without inaccuracies or omissions."
  },
  "559": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the clinical scenario, drug, and general mechanism (competitive inhibition of cytochrome P450 enzymes), but it omits the specific enzyme (CYP2A6) named in the reference and instead lists CYP1A2 and CYP2C19, which is a moderate factual omission."
  },
  "560": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough clinical explanation and correctly identifies dopamine reuptake inhibition as a key mechanism, but it omits that norepinephrine reuptake inhibition is the primary pathway referenced in the question and reference answer; this is a moderate omission."
  },
  "561": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant additional details (e.g., summary table, guideline references) without any inaccuracies or omissions."
  },
  "562": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the superior soft tissue delineation of MRI and its importance for surgical planning, but incorrectly states that MRI is not strictly mandatory, which contradicts the reference answer and may lead to omission of a crucial imaging step; this represents a moderate factual inaccuracy."
  },
  "563": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies fondaparinux, its mechanism via antithrombin III, and its lack of cross-reactivity with HIT antibodies, but it omits the key reference term \"serine proteinase inhibitors (serpins) potentiators\" and instead uses the less precise \"indirect factor Xa inhibitor,\" missing the specific pharmacological class required."
  },
  "564": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale but incorrectly states that grade 3 histology alone does not justify comprehensive regional nodal irradiation, directly contradicting the reference answer's key clinical fact; this is a moderate factual error, though the rest of the content is relevant and not unsafe."
  },
  "565": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies increased β-oxidation of fatty acids as the key process and provides relevant mechanistic detail, but emphasizes PPAR-α activation as the primary answer, which is upstream of the specific process asked (oxidation activity). There are no inaccuracies, but the focus could be more directly on β-oxidation itself."
  },
  "566": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies prostaglandin (EP) receptors as the primary target and provides accurate, relevant detail about receptor subtypes and drug mechanism, but does not explicitly use the term \"prostaglandin receptor agonists\" as in the reference; this is a minor wording inaccuracy."
  },
  "567": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the indication for endocrine therapy, cites relevant guidelines, and provides appropriate rationale without any inaccuracies or omissions."
  },
  "568": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the rationale and guideline recommendations, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "569": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging, guideline-based rationale, and appropriate first-line treatment recommendations, with no inaccuracies or omissions."
  },
  "570": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the directly inhibited enzyme and notes both COX-1 and COX-2 isoforms, covering over 90% of key facts. However, it does not specifically name \"Prostaglandin G/H Synthase 1 (Cyclooxygenase-1)\" as in the reference, representing a minor omission in specificity."
  },
  "571": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and emphasizes COX-2 as the primary mediator of anti-inflammatory effects, which is accurate and clinically relevant. However, the reference answer specifies \"Prostaglandin G/H Synthase (Cyclooxygenase, COX-1/COX-2)\" as the most direct target, so omitting COX-1 as a target is a minor omission."
  },
  "572": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that a 6 mm nodule warrants 3–6 month follow-up, and provides relevant, accurate context from guidelines without any inaccuracies or omissions."
  },
  "573": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug (atovaquone) and its mechanism (mitochondrial electron transport inhibition), but does not explicitly state the reference answer's class (\"nucleic acid synthesis inhibitors\"), which is the best pharmacologic description per the question; thus, it covers most but not all key facts."
  },
  "574": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies dopamine's dose-dependent adrenergic agonism, and accurately details the molecular mechanism (Gs protein-coupled β1-adrenergic receptor activation and cAMP increase) without inaccuracies or omissions."
  },
  "575": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the precise mechanism of gentian violet is not fully defined, but then adds multiple proposed mechanisms not supported by current pharmacological references, which overstates the certainty and may mislead; this constitutes minor errors and overinterpretation, but no unsafe advice."
  },
  "576": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of evidence for RET inhibitors in squamous histology, references current guidelines, and correctly prioritizes standard chemotherapy/immunotherapy; no inaccuracies or omissions are present."
  },
  "577": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites relevant guidelines and studies, and contains no inaccuracies or omissions."
  },
  "578": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies gentian violet and states that its precise mechanism is incompletely understood, matching the reference. It adds plausible proposed mechanisms (DNA binding, cell wall disruption) as possibilities, but clearly qualifies that these are not fully established, which is accurate and clinically relevant. There are no inaccuracies, but the answer could be slightly more concise in directly stating the mechanism is unknown, hence a minor wording inaccuracy."
  },
  "579": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism of abatacept and its interaction with CD80/86, but it names CD80/86 as the primary molecular target rather than CTLA-4, which is the focus of the reference answer; this is a minor wording inaccuracy, as the therapeutic effect is mediated by CTLA-4 binding but the direct target is CD80/86."
  },
  "580": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that immediate annual surveillance is standard, omitting the required initial 6-monthly CT phase and thus misrepresents the protocol; this is a major inaccuracy regarding follow-up standards."
  },
  "581": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides nuanced discussion, but it contradicts the reference by stating endocrine therapy alone is appropriate for some premenopausal women with scores 16–25, whereas the reference states chemotherapy is generally required due to proven benefit; this is a moderate factual inaccuracy."
  },
  "582": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that immunotherapy monotherapy is inadequate, emphasizes the necessity of platinum-based chemotherapy, and provides relevant supporting evidence and guidelines without any inaccuracies or omissions."
  },
  "583": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "584": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly states that concurrent chemoradiation is generally preferred, whereas the reference specifies that both approaches are equally acceptable due to lack of evidence for superiority; otherwise, the answer is thorough and covers most key facts, but this overstatement is a moderate factual inaccuracy."
  },
  "585": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the evidence for durvalumab and osimertinib, and correctly notes the lack of data for osimertinib post-chemoradiation, but it ultimately recommends durvalumab as standard, which is not aligned with the reference answer prioritizing osimertinib due to EGFR mutation; this represents a moderate omission in clinical prioritization."
  },
  "586": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes when SRS alone is appropriate, and when surgery should be prioritized, with no inaccuracies or omissions. Additional content is correct, relevant, and well-supported."
  },
  "587": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), including both COX-1 and COX-2, as the target, and explains the mechanism, but does not specify COX-2 as the primary target as in the reference; this is a minor omission."
  },
  "588": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies pentoxifylline, its hemorheologic effects, and explicitly states that the precise molecular mechanisms are not fully elucidated, matching the reference. It adds accurate, relevant mechanistic details (PDE inhibition, cAMP), but this does not contradict the reference; however, the answer could be seen as slightly overstating the certainty of the mechanism, which is a minor wording inaccuracy."
  },
  "589": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly distinguishing between T3 and T4 nodules and emphasizing the greater selectivity and controversy for surgery in T4 cases, but slightly overstates the impact of anatomical location on eligibility, whereas the reference states anatomical location alone does not preclude surgery; this is a minor wording inaccuracy."
  },
  "590": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites supporting guidelines and trials, and contains no inaccuracies or omissions."
  },
  "591": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains that radiotherapy is an option for unresectable local disease, but it contradicts the reference by stating that recommendations for local therapy do not implicitly exclude unresectable cases, whereas the reference asserts that such recommendations are based on resectability. This represents a moderate factual inaccuracy regarding the implicit assumptions underlying guideline recommendations."
  },
  "592": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies FXR as the primary target, omitting the key fact that thyroid hormone receptor agonists are the correct class; while the explanation is detailed and relevant, the main factual error significantly reduces the score."
  },
  "593": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, explicitly states that the precise mechanism is unknown, and provides additional clinically relevant, accurate context without any inaccuracies or omissions."
  },
  "594": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the role of re-resection and the controversy around PORT, but incorrectly states that observation alone is \"not routinely recommended\" and \"not standard,\" which contradicts the reference answer that observation is appropriate in the absence of residual disease; this is a moderate factual inaccuracy."
  },
  "595": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts about inhibition of folate synthesis via PABA antagonism, and correctly identifies the drug class and its mechanism. However, it adds mechanistic details about effects on lymphocytes and nucleotide synthesis that, while accurate, go slightly beyond the reference and could be considered a minor wording inaccuracy since the main therapeutic action in autoimmune disease is not fully established to be via folate inhibition in host cells."
  },
  "596": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizes guideline recommendations for biopsy and reassessment, and provides relevant context, but its initial statement that confirmation is \"not strictly necessary\" slightly understates the importance of current best practice, which is to base treatment on the most recent pathology; this constitutes a minor wording inaccuracy."
  },
  "597": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishing recommendations by menopausal status, explaining the rationale, and noting when aromatase inhibitors may be preferred; all additional content is correct and clinically relevant."
  },
  "598": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant chemotherapy may be started in the late third trimester, whereas the reference specifies it should be deferred until after delivery; this is a moderate factual error. While the answer is detailed and evidence-based, it contradicts the key clinical recommendation in the reference."
  },
  "599": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pre-mRNA splicing machinery/spliceosome as the primary molecular target, provides accurate and clinically relevant context, and contains no inaccuracies or omissions."
  },
  "600": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the general mechanism of vitamin K (menadiol) in γ-carboxylation of clotting factors, but it fails to acknowledge that the precise mechanism by which menadiol benefits inherited factor II deficiency is not clearly defined, as stated in the reference. This omission of the key uncertainty reduces the score."
  },
  "601": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of ROS1 rearrangements in squamous histology and the need for confirmatory testing, but it overstates the appropriateness of ROS1-targeted therapy by not emphasizing that squamous histology is generally an exclusion except in rare, carefully validated cases, and does not sufficiently highlight the risk of misclassification."
  },
  "602": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies cyclooxygenase inhibition as the drug action, and provides correct, clinically relevant elaboration without any inaccuracies or omissions."
  },
  "603": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical syndrome and the commonly used therapy (somatostatin analogs targeting SSTR2), but it misses the reference answer's key fact that the question specifically describes interferon alpha therapy and its receptor, not somatostatin analogs. Thus, it covers about 70-89% of key facts but omits the central molecular target."
  },
  "604": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly classifies the disease as stage IV due to the contralateral nodule, and appropriately recommends metastatic protocols; all additional explanations are accurate and clinically relevant."
  },
  "605": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the specific class (beta-lactam antibiotics) and explains the mechanism, but it does not directly state the broader pharmacological class \"enzyme inhibitors\" as in the reference answer, omitting the key general classification."
  },
  "606": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, clearly distinguishing between routine surveillance (where PET/CT and brain MRI are not indicated) and the scenario of a new nodule (where both are indicated for recurrence workup), with accurate, relevant explanations and no inaccuracies or omissions."
  },
  "607": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant and accurate detail about preoperative assessment and decision-making, and contains no inaccuracies or omissions."
  },
  "608": {
    "score": 4.0,
    "explanation": "4: The model answer correctly describes the RNA interference mechanism and its post-transcriptional gene silencing effect, but does not explicitly state \"nucleic acid synthesis inhibition\" as the class, which is the key fact in the reference answer; otherwise, it is accurate and thorough."
  },
  "609": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that ALND may be omitted after neoadjuvant therapy in cN1 patients with a positive sentinel node, which contradicts current guidelines; this is a moderate factual error. While the answer is detailed and references guidelines, it misapplies the Z0011 criteria to a population (post-neoadjuvant cN1) where ALND is still indicated, thus covering less than 70% of key facts and including a significant error."
  },
  "610": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of pulmonary fibrosis and smoking on malignancy risk, references relevant guidelines, and provides clinically relevant rationale without any inaccuracies or omissions."
  },
  "611": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need to distinguish between synchronous primaries and metastatic disease, and the importance of pathology and radiology in making this determination. However, it does not clearly state that when both lesions are potentially curable, they should be managed as two primaries (as per the reference), and instead emphasizes defaulting to metastatic management unless proven otherwise, which is a moderate omission."
  },
  "612": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts and provides accurate, relevant detail about vitamin A metabolism and its role in rhodopsin regeneration, but it emphasizes \"nutritional/cofactor replacement\" rather than specifically highlighting \"enzyme interactions\" as the primary pharmacological mechanism, which is a minor wording inaccuracy."
  },
  "613": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the mechanism and identifies beta-lactam antibiotics/cell wall synthesis inhibitors, but does not explicitly state \"enzyme inhibitors\" as required by the reference answer, missing the key classification term."
  },
  "614": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing selpercatinib or pralsetinib as first-line therapy and relegating cabozantinib to a secondary role if selective inhibitors are unavailable; all additional content is accurate, relevant, and guideline-based."
  },
  "615": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CSF1R as the receptor, covers all key clinical facts from the reference, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "616": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that brain MRI is not routinely recommended but incorrectly recommends FDG-PET/CT as routine surveillance, whereas the reference specifies neither is routinely indicated without symptoms or evidence of dissemination; this is a moderate factual error."
  },
  "617": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) enzymes as the molecular target and explains the roles of COX-1 and COX-2, but does not specifically name \"Prostaglandin G/H Synthase 1 (COX-1)\" as the primary target, which is a minor omission."
  },
  "618": {
    "score": 0.0,
    "explanation": "0: The model answer directly contradicts the reference by recommending immediate switching to selpercatinib, which is not supported by the reference or standard sequencing; this is a clinically unsafe recommendation."
  },
  "619": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizing that chemotherapy indication is based on tumor biology and risk factors rather than histological subtype alone, and provides accurate, clinically relevant explanations without any inaccuracies or omissions."
  },
  "620": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies thrombin (factor IIa) as the primary target via antithrombin III, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "621": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies COX-2 as a direct target and explains aspirin's mechanism, but does not specifically name \"Prostaglandin G/H Synthase 2 (COX-2)\" as in the reference; it also includes COX-1, which is less relevant to the anti-inflammatory effect, making this a minor inaccuracy."
  },
  "622": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies heparins and accurately describes their mechanism, but the reference answer specifically asks for \"thrombin inhibitors\" as the class, not heparins; thus, the model misses the key fact of the reference's broader pharmacological classification."
  },
  "623": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly states that adjuvant HER2 therapy is indicated regardless of pCR or initial nodal status, and clarifies pertuzumab use for node-positive cases; all additional content is accurate and clinically relevant."
  },
  "624": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly prioritizing re-resection if feasible and accurately describing chemoradiation as an alternative when re-resection is not possible; all additional content is correct, relevant, and guideline-based."
  },
  "625": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies botulinum toxin, explains its mechanism (inhibition of presynaptic acetylcholine release), and relates it to the clinical scenario, but does not explicitly use the reference's precise pharmacological class term \"acetylcholine release inhibitors,\" which is a minor wording inaccuracy."
  },
  "626": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant rationale, cites supporting guidelines and trials, and contains no inaccuracies or omissions."
  },
  "627": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the clinical scenario and the mechanism of corticosteroids inhibiting phospholipase A2, but it does not identify lipoxygenase as the enzyme class most directly relevant to the question's focus on leukotriene synthesis, missing a key fact from the reference answer."
  },
  "628": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, accurately states that routine brain MRI is not recommended in asymptomatic patients, details surveillance with chest CT, and appropriately notes exceptions and guideline sources; no inaccuracies or omissions."
  },
  "629": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "630": {
    "score": 2.0,
    "explanation": "2: The model answer correctly explains that the classification of two primaries is independent of curability, but it misses the key clinical fact that the dual primary approach (with curative intent) is only applicable if both lesions are individually curable; this is a moderate omission."
  },
  "631": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant guideline citations, and appropriately notes the rare exception of reversible tumor-related decline; there are no inaccuracies or omissions."
  },
  "632": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the clinical scenario and mechanism of valproic acid but incorrectly names GABA transaminase as the primary molecular target, rather than the GABA B receptor as specified in the reference; this is a moderate factual error."
  },
  "633": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts, correctly identifies the drug and its class, and provides accurate, relevant additional detail about its mechanism and clinical use without any inaccuracies or omissions."
  },
  "634": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies glucocorticoids as the treatment and thoroughly explains their mechanism, but it does not explicitly use the term \"glucocorticoid receptor agonists\" as in the reference answer; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "635": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the likely mechanism (Nrf2 pathway activation), but does not align with the reference answer's emphasis that the mechanism is \"unknown\" and not fully elucidated; thus, it covers 70-89% of key facts but misses the core classification required."
  },
  "636": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies viral DNA polymerase as the principal target, provides accurate and clinically relevant explanation regarding cidofovir, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "637": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism as inhibition of microtubule polymerization and provides relevant details about benzimidazoles, but it does not directly state \"enzyme inhibitors\" as the general class, missing the key fact required by the reference answer."
  },
  "638": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies COX-2 as the molecular target, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "639": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by denying that radiotherapy is the key determinant for more intensive follow-up, omitting the central fact that initial radiotherapy warrants a more frequent imaging schedule; this is a major inaccuracy."
  },
  "640": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the concept of suicide (mechanism-based irreversible) inhibitors but fails to specify the relevant cytochrome P450 isoenzyme (CYP2B6) as in the reference answer, and instead discusses CYP2C9 and benzimidazoles, which are not the primary agents or mechanisms for Fasciola hepatica. This represents a moderate factual omission and some irrelevant content."
  },
  "641": {
    "score": 3.0,
    "explanation": "3: The model answer correctly emphasizes the need for rapid symptom relief with SVC stenting and acknowledges the role of chemoradiation for definitive therapy, but it incorrectly prioritizes exclusive stenting over initial concurrent chemoradiation, missing that chemoradiation is generally recommended as first-line unless symptoms are rapidly worsening; this is a moderate omission."
  },
  "642": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies diethylcarbamazine and its mechanism involving cyclooxygenase inhibition, but it incorrectly names the drug class as \"piperazine derivatives\" rather than \"cyclooxygenase inhibitors,\" missing the direct answer required by the question; otherwise, clinical details and mechanistic explanation are accurate."
  },
  "643": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise mechanism is not fully understood and provides accurate, relevant details about thalidomide’s immunomodulatory actions, but it goes beyond the reference by listing plausible mechanisms rather than simply stating the mechanism is unknown, which constitutes a minor wording inaccuracy."
  },
  "644": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant, up-to-date details without any inaccuracies or omissions."
  },
  "645": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies pyrantel pamoate and accurately describes its action as a nicotinic acetylcholine receptor agonist causing persistent depolarization, but it does not mention cholinesterase inhibition, which is the specific molecular mechanism referenced in the key."
  },
  "646": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the agent as a retinoid and accurately describes its nuclear receptor-mediated modulation of gene transcription, but it does not mention enzyme interactions or modulation of skin enzyme activity, which is the key fact in the reference answer."
  },
  "647": {
    "score": 3.0,
    "explanation": "3: The model answer covers the relevant drug classes and mechanisms but introduces confusion by emphasizing heme polymerase inhibition (the primary action of quinolines) rather than directly focusing on nucleic acid synthesis inhibition, as specified in the reference. It also discusses artesunate, which is not a nucleic acid synthesis inhibitor, leading to minor inaccuracies and some irrelevant content."
  },
  "648": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, includes relevant guideline citations, and adds correct, clinically relevant context without any inaccuracies or omissions."
  },
  "649": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies glucocorticoid receptor activation as the primary pathway and provides accurate, relevant mechanistic detail, but slightly overemphasizes NF-κB inhibition as the singular pathway rather than the broader glucocorticoid receptor agonism, which is the reference answer's focus; this is a minor wording inaccuracy."
  },
  "650": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that PMRT can be omitted despite the tumor size exceeding 5 cm, which is a critical criterion; it acknowledges the threshold but downplays its significance, leading to a moderate factual inaccuracy."
  },
  "651": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough, guideline-based discussion and correctly states that durvalumab remains standard of care, but it incorrectly concludes that osimertinib should not be prioritized, which is at odds with the reference answer’s clear recommendation to prioritize osimertinib in EGFR-mutant cases; this represents a significant omission of the key clinical fact."
  },
  "652": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and clearly states that molecular profiling should be prioritized regardless of neurological symptoms, with no inaccuracies or omissions."
  },
  "653": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class and its mechanism—binding to ergosterol and forming pores to increase membrane permeability—covering over 90% of key facts. However, it does not explicitly mention \"disruption of ergosterol synthesis\" as in the reference, but rather describes direct binding and pore formation, which is accurate for polyenes; this is a minor wording difference, not a factual error."
  },
  "654": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly stating that systemic therapy is not recommended in the presence of severe uncontrolled comorbidities and that guidelines assume their absence; however, it could be clearer that the recommendation does not \"automatically\" assume absence, but rather that comorbidities must be specifically evaluated, which is a minor wording inaccuracy."
  },
  "655": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies interferon-alpha and its immunomodulatory, cytokine-mediated mechanism, which fits under the broad class of biological response modifiers; however, it does not explicitly use the term \"biological response modifiers,\" which is the key reference phrase, representing a minor wording inaccuracy."
  },
  "656": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that observation is generally not recommended in asymptomatic patients with progression, which contradicts the reference's emphasis that observation remains a valid option based on individual factors; this represents a moderate omission and some misleading wording."
  },
  "657": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing retinoid modulation of epithelial and mucin-related enzymes via nuclear receptor-mediated gene transcription, with no inaccuracies or omissions."
  },
  "658": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies muscarinic M3 receptors as the primary target, whereas the reference specifies adrenergic beta2-agonists; while the explanation is detailed and relevant, this represents a moderate factual error regarding the drug class."
  },
  "659": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that FDG-PET/CT is appropriate for all asymptomatic patients with new radiographic abnormalities, which overstates guideline recommendations; it misses the nuance that PET/CT should be reserved for cases with clinical suspicion, not for all incidental findings, constituting a moderate factual error."
  },
  "660": {
    "score": 4.0,
    "explanation": "4: The model answer covers all major clinical facts, correctly states that low-dose non-contrast CT is not appropriate for surveillance, and emphasizes the need for standard-dose CT (with or without contrast). However, it omits the specific surveillance intervals (every 3–6 months for 3 years, then every 6 months for 2 years, then annual), which is a minor omission."
  },
  "661": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the class as anti-herpetic nucleoside analogs and thoroughly explains the mechanism, but it does not explicitly use the term \"DNA polymerase inhibitors\" as in the reference answer, which is a minor wording inaccuracy."
  },
  "662": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides additional relevant detail about diagnostic criteria and guidelines, and contains no inaccuracies or omissions."
  },
  "663": {
    "score": 3.0,
    "explanation": "3: The model answer identifies EGFR as the targeted receptor, which is incorrect; the reference specifies IGF-1R. While the answer provides relevant discussion and reasoning, it ultimately names the wrong receptor, missing the key fact required."
  },
  "664": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, cites supporting evidence and guidelines, and contains no inaccuracies or omissions."
  },
  "665": {
    "score": 2.0,
    "explanation": "2: The model answer identifies L-type calcium channels as the primary target, which is incorrect for the scenario described (the reference answer is beta-1 adrenergic receptor). While the explanation is logical for calcium channel blockers, it misses the key fact that the question describes a beta-1 selective blocker; this is a moderate factual error."
  },
  "666": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains guideline recommendations, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "667": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the principal molecular target and provides relevant, accurate explanation, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference, representing a minor omission in precision."
  },
  "668": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies histone deacetylase as the primary molecular target, explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "669": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and relevant guideline-based explanations, and contains no inaccuracies or omissions."
  },
  "670": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly emphasizes neoadjuvant chemotherapy as appropriate and guideline-supported, and provides relevant rationale. However, it slightly overstates immediate surgery as an \"acceptable\" option, whereas guidelines generally prefer neoadjuvant therapy in this context, making this a minor wording inaccuracy."
  },
  "671": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly identifies iron overload as the likely cause, explains the chelation mechanism, and describes how chelators like deferoxamine work. There is a minor distraction with discussion of copper and Kayser-Fleischer rings, but no clinically significant errors or omissions."
  },
  "672": {
    "score": 3.0,
    "explanation": "3: The model answer is thorough and accurate regarding current guidelines, correctly stating that ALND is standard after neoadjuvant therapy if residual nodal disease remains, but it contradicts the reference answer, which allows omission of ALND in the case of only one positive node. This represents a moderate factual discrepancy, as the model overstates the necessity of ALND and does not acknowledge evolving practice reflected in the reference."
  },
  "673": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending early initiation of ALK inhibitor before completing systemic therapy, which is not standard and could be unsafe; this is a major inaccuracy."
  },
  "674": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target enzyme and explains the mechanism, but it does not specify COX-2 (prostaglandin G/H synthase 2), which is the key isoform relevant to the reference answer. The explanation is otherwise accurate and relevant."
  },
  "675": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies SNAP-25 as the direct molecular target, explains the mechanism of botulinum toxin, and accurately links acetylcholine inhibition to symptomatic relief, fully covering all key clinical facts with relevant, accurate detail."
  },
  "676": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the impact of mediastinal node positivity on staging and management, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "677": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the mechanism as inhibition of nucleic acid synthesis, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "678": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies serine proteases (including thrombin and factor Xa) as the molecular targets and explains the mechanism, but does not explicitly state \"thrombin inhibitors\" as the primary class, which is the key fact in the reference answer; otherwise, the explanation is accurate and relevant."
  },
  "679": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of cantharidin’s clinical effect and histological action, but it does not directly state that the mechanism is \"unknown cellular or molecular interaction\" as required by the reference; instead, it infers a partially understood mechanism, missing the key point that the mechanism is officially unknown."
  },
  "680": {
    "score": 2.0,
    "explanation": "2: The model answer identifies CYP3A inhibitors rather than the reference's CYP2D6 inhibitors, which is a moderate factual error regarding the specific enzyme relevant to the question, despite otherwise correct and relevant explanation."
  },
  "681": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly emphasizes the role of EGFR TKIs in CNS disease, references current guidelines, and appropriately notes radiotherapy is reserved for symptomatic or emergent cases; no inaccuracies or omissions."
  },
  "682": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise mechanism is unknown and provides additional, factually accurate, and clinically relevant details about proposed immunomodulatory effects; there are no inaccuracies, but the reference answer is more concise, and the model's extra detail is not strictly required."
  },
  "683": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathological confirmation, explains the limitations of imaging, cites relevant guidelines, and appropriately notes rare exceptions, with no inaccuracies or omissions."
  },
  "684": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately contrasts the imaging schedules, explains the rationale for increased surveillance, and cites relevant guidelines. There are no inaccuracies or omissions."
  },
  "685": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts and provides additional relevant details about diagnostic criteria and clinical significance, but it introduces specific histologic and molecular criteria not mentioned in the reference, which, while accurate, slightly shifts emphasis from the reference's focus on technical resectability and curability; otherwise, there are no inaccuracies or unsafe statements."
  },
  "686": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies ethosuximide, its main proposed mechanism (T-type calcium channel inhibition), and acknowledges that the precise mechanism is not fully understood, but it does not explicitly state that the mechanism is unknown as in the reference; this is a minor wording inaccuracy."
  },
  "687": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the generally accepted mechanism of vitamin K in coagulation, but it does not acknowledge that the precise cellular or molecular mechanism in premature infants is currently unknown, as stated in the reference answer; this is a moderate omission."
  },
  "688": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "689": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and guideline-based details, and includes relevant, correct additional information without any inaccuracies or omissions."
  },
  "690": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the proposed mechanisms of povidone-iodine but fails to emphasize that the precise cellular or molecular mechanism is unknown, as required by the reference answer; thus, it covers most key facts but misses the central point."
  },
  "691": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing that broad molecular profiling is standard of care but stating that isolated ERBB2 testing suffices for drug eligibility, which is a minor wording inaccuracy compared to the reference's emphasis on profiling as a prerequisite."
  },
  "692": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the indication for brain MRI in this staging, the risk of nephrogenic systemic fibrosis with gadolinium in severe CKD, and the need to consider non-contrast MRI or alternatives. Additional content is accurate, relevant, and guideline-based."
  },
  "693": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately discusses the marginal benefit of chemotherapy in small, node-negative TNBC, addresses cardiac comorbidity and anthracycline risk, and appropriately concludes that chemotherapy is generally not indicated; all additional content is correct and clinically relevant."
  },
  "694": {
    "score": 3.0,
    "explanation": "3: The model answer covers the downstream mechanism (transcriptional upregulation of melanogenic enzymes due to DNA damage from psoralen-UVA), but omits the most direct process—photoactivation (photoabsorption) of psoralen by UVA—which is the key fact in the reference answer."
  },
  "695": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that ECOG 2 is not an exclusion criterion, and provides additional, relevant context about trial data, labeling, and guidelines without any inaccuracies or omissions."
  },
  "696": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant guideline-based rationale, and includes no inaccuracies or omissions; all extra content is accurate and clinically pertinent."
  },
  "697": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about approval, supporting studies, guidelines, and toxicity considerations, and contains no inaccuracies or omissions."
  },
  "698": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies dopamine (D2) receptor antagonism as the mechanism, and provides accurate, relevant additional explanation without any inaccuracies or omissions."
  },
  "699": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism and provides relevant examples, but uses \"anti-herpetic nucleoside analogues\" rather than the more general \"DNA polymerase inhibitors\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "700": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly stating that N3 involvement precludes surgery as standard initial therapy and explaining why, but its mention of rare, exceptional surgical cases introduces a minor nuance not present in the reference, making the answer slightly less definitive."
  },
  "701": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), specifically COX-1 and/or COX-2, as the molecular target and provides accurate, relevant mechanistic detail, but does not explicitly specify \"Prostaglandin G/H Synthase 2 (COX-2)\" as the primary target, which is a minor omission."
  },
  "702": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that adjuvant radiotherapy is not routine and depends on clinicopathological factors, and provides additional relevant, correct detail without inaccuracies or omissions."
  },
  "703": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies protein kinase C as the primary intracellular enzyme inhibited by gold-based therapy and provides relevant mechanistic detail, but it omits the specific isoform \"iota type\" mentioned in the reference answer, which is a minor omission."
  },
  "704": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing that perioperative therapy is only appropriate if the patient is a surgical candidate, and that poor PFTs generally preclude surgery and thus perioperative therapy; it also correctly describes the alternative of definitive chemoradiotherapy, with no inaccuracies or omissions."
  },
  "705": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need for pathologic confirmation, explains why imaging alone is insufficient, and provides relevant guideline-based context without any inaccuracies or omissions."
  },
  "706": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the likely infection and treatment, and accurately describes ivermectin’s mechanism, but it does not address the reference answer’s focus on enzyme inhibition as the general mechanism; thus, it misses the key fact required by the question."
  },
  "707": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class, mechanism, and clinical context, but incorrectly states that SSTR2 is the primary target, whereas the reference specifies SSTR5; this is a moderate factual error, though much of the relevant information is otherwise accurate."
  },
  "708": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the disease, the hormone (calcitonin), and its inhibition of osteoclasts, but incorrectly states that calcitonin binds to hydroxyapatite rather than to osteoclast receptors; it omits the reference answer’s focus on structural macromolecules like collagen, covering about 70-89% of key facts."
  },
  "709": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class as prostacyclin analogs (prostanoids), explains the mechanism via G protein-coupled IP receptors, and provides relevant clinical context without inaccuracies or omissions."
  },
  "710": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug as a keratolytic agent and provides relevant explanation, but it does not explicitly state that the specific cellular or molecular mechanism is unknown, which is the key fact in the reference answer."
  },
  "711": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "712": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"tryptophan hydroxylase\" as the inhibited enzyme and provides accurate, relevant explanation, but omits the specific isoform \"tryptophan 5-hydroxylase 1\" named in the reference, which is a minor omission."
  },
  "713": {
    "score": 4.0,
    "explanation": "4: The model answer covers all the key facts regarding the necessity and rationale for broad molecular profiling, but omits mention of several additional relevant targets (BRAF, NTRK, MET exon 14, RET, HER2) included in the reference answer; otherwise, the content is accurate and clinically relevant."
  },
  "714": {
    "score": 5.0,
    "explanation": "5: The model answer correctly states that supplemental oxygen does not provide a pharmacological protective effect against oxidative damage, covers all key clinical facts from the reference, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "715": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating that more frequent imaging is not needed for residual abnormalities, omitting the key fact that such findings do warrant closer surveillance; this is a major inaccuracy."
  },
  "716": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies thioredoxin reductase as the inhibited enzyme and mentions the relevant drug, but omits the specific mitochondrial isoform (\"thioredoxin reductase 2, mitochondrial\") referenced in the key answer."
  },
  "717": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that adjuvant therapy is standard but may be contraindicated by significant pulmonary impairment, and emphasizes individualized decision-making. However, it is less definitive than the reference in stating that significant impairment would contraindicate therapy, and could be clearer that observation is favored in such cases."
  },
  "718": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly lists relevant genes, addresses the role of prior radiotherapy, and provides accurate, guideline-based rationale without any inaccuracies or omissions."
  },
  "719": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class as DNA methyltransferase inhibitors (hypomethylating agents) and explains their mechanism, but it does not explicitly state \"nucleoside synthesis inhibitors\" as in the reference, missing the key fact required by the question."
  },
  "720": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate mechanism for topical calcineurin inhibitors, but this is not the drug referenced in the question or the reference answer (clioquinol). It does not state that the mechanism of clioquinol in lichenoid dermatitis is unknown, which is the key fact, and instead speculates at length about other agents, resulting in a moderate omission."
  },
  "721": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that adjuvant therapy is not routinely indicated, and surveillance is sufficient in the absence of high-risk features; additional content is correct, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "722": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of automatic eligibility for HER2-targeted therapy in squamous histology, the primacy of PD-L1 status, and the investigational nature of HER2-targeted therapy in this context, with no inaccuracies or omissions."
  },
  "723": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "724": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites supporting evidence and guidelines, and includes only relevant, correct additional information without any inaccuracies or omissions."
  },
  "725": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that surgery is not preferred in the context of severely impaired pulmonary function and that SBRT is the recommended alternative; all additional content is accurate and clinically relevant."
  },
  "726": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately stating that the mechanism is classified as unknown/not fully defined in major databases, while providing correct and relevant additional detail about the presumed DNA disruption mechanism."
  },
  "727": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly prioritizing endobronchial intervention in cases of critical airway compromise and referencing guidelines, but introduces a nuanced distinction for mild/moderate symptoms not explicitly in the reference, which could be seen as a minor omission in clarity regarding prioritization."
  },
  "728": {
    "score": 4.0,
    "explanation": "4: The model answer accurately describes the molecular mechanism—binding to cytoplasmic glucocorticoid receptors, nuclear translocation, and gene transcription modulation—but omits explicit mention of mineralocorticoid receptor agonism, which is also a key therapeutic mechanism in primary adrenal insufficiency."
  },
  "729": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that adjuvant chemotherapy with trastuzumab is indicated for node-negative, HER2-positive tumors >1 cm, but it overstates the routine use of pertuzumab in node-negative cases and does not clarify that dual anti-HER2 therapy (trastuzumab plus pertuzumab) is primarily indicated for node-positive or high-risk disease, missing the key nuance of the reference answer."
  },
  "730": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies calcium channel blockers as the drug class, explains the mechanism (L-type calcium channel inhibition), and provides relevant examples without inaccuracies or omissions."
  },
  "731": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly noting that pulmonary fibrosis increases cancer risk and justifies 3–6 month follow-up, and that this alters the standard approach; all additional content is accurate, relevant, and well-supported."
  },
  "732": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "733": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies 5α-reductase (type II) as the target enzyme, explains its role in converting testosterone to DHT, and mentions the relevant medication (finasteride); all key facts are covered with accurate, clinically relevant extra detail."
  },
  "734": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the need to await biomarker results before starting therapy, details exceptions for urgent cases, and provides relevant guideline references without inaccuracies or omissions."
  },
  "735": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the GABA_A receptor instead of the GABA_B receptor, which is the direct target of baclofen—the classic centrally acting antispastic agent in this scenario. While the explanation is detailed, the main factual error is moderate and central to the question."
  },
  "736": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes metronidazole’s general mechanism but fails to emphasize that, in deep abscesses, the precise molecular or cellular interactions responsible for its effectiveness are unknown, as stated in the reference. This constitutes a moderate omission."
  },
  "737": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant additional context, and contains no inaccuracies or omissions."
  },
  "738": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, explicitly confirming the appropriateness of larotrectinib, the necessity of broad molecular profiling with adequate tissue, and guideline support; all additional content is accurate and clinically relevant."
  },
  "739": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, references guidelines, and contains no inaccuracies or omissions."
  },
  "740": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate, clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "741": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and correctly cites guidelines and evidence; there are no omissions or inaccuracies."
  },
  "742": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing the need to continue ovarian suppression with ongoing endocrine therapy and providing rationale and guideline support. However, it introduces a minor inaccuracy by suggesting ovarian suppression may be stopped if switching to chemotherapy, which is not universally recommended and could be misleading; thus, a minor deduction is warranted."
  },
  "743": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference by stating that the recommendation does not implicitly require absence of preoperative systemic therapy, missing the key nuance that the classic recommendation is based on untreated nodal burden; while it provides some relevant context about guidelines, it omits the critical distinction and thus covers less than 70% of key facts."
  },
  "744": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as increased calcium influx via ion channels and links this to sustained muscle contraction, covering nearly all key facts. However, it introduces some ambiguity by referencing both ligand-gated and voltage-gated channels, whereas the reference specifies direct action on calcium channels without this distinction; this constitutes a minor wording inaccuracy."
  },
  "745": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including prioritization of NTRK inhibitors for systemic and intracranial disease, the exception for urgent radiotherapy in severe symptoms, and provides accurate, relevant additional detail without inaccuracies or omissions."
  },
  "746": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the risks of cumulative toxicity, prioritizes systemic therapy, and appropriately notes that re-irradiation is only for highly selected cases; all additional details are correct and clinically relevant."
  },
  "747": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies DNA methyltransferase as the enzyme inhibited by hypomethylating agents in MDS and provides a thorough, accurate explanation. However, it does not specify the exact isoform (tRNA (Cytosine(38)-C(5))-Methyltransferase) as in the reference, representing a minor omission in precision."
  },
  "748": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides detailed, accurate rationale, but it introduces nuanced discussion about radiotherapy not being routinely indicated for N1/R0 cases, which, while correct, slightly diverges from the reference's more general endorsement; this constitutes a minor omission in directness but does not alter the clinical meaning."
  },
  "749": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the insulin receptor as a transmembrane receptor with intrinsic tyrosine kinase activity and explains the mechanism, but does not explicitly use the term \"insulin receptor agonists\" as in the reference answer; otherwise, all key facts are present and accurate."
  },
  "750": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the rarity and limited evidence for EGFR-targeted therapy in squamous cell carcinoma with EGFR exon 20 insertions, and appropriately emphasizes standard care and the need for caution. No inaccuracies or omissions are present."
  },
  "751": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the role of stenting for severe symptoms and chemoradiation for stable patients, but it incorrectly prioritizes chemoradiation over stenting in all clinically stable patients, omitting that stenting is often still prioritized for rapid symptom relief even in stable cases; this is a moderate omission."
  },
  "752": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "753": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the general class as \"melatonin receptor agonists\" and accurately explains the mechanism, but does not use the broader term \"hormone receptor agonists\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "754": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that the drug’s precise molecular mechanism is not fully elucidated and describes nonspecific disruption of fungal cell membranes, but it incorrectly names undecylenic acid as the agent rather than clioquinol, which is the focus of the reference answer; this represents a moderate factual error."
  },
  "755": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies Janus kinase (JAK) as the primary molecular target, whereas the reference specifies the glucocorticoid receptor; this is a moderate factual error, though the rest of the explanation is relevant and not unsafe."
  },
  "756": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides detailed, guideline-based reasoning, but it incorrectly states that sequential chemoradiation is \"preferred\" and that concurrent chemoradiation is \"not routinely recommended,\" which overstates the reference's more neutral stance that neither is universally preferred; this is a minor but meaningful inaccuracy."
  },
  "757": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately discusses the roles of chemoradiation, radiotherapy, and SVC stenting, and provides clinically relevant context for immediate and long-term management without inaccuracies or omissions."
  },
  "758": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the roles of amivantamab-vmjw, immunotherapy, and chemotherapy in EGFR exon 20 insertion NSCLC, and provides relevant guideline context without inaccuracies or omissions."
  },
  "759": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishing the indications for broad molecular profiling and PD-L1 testing by histologic subtype, and provides correct, relevant explanations without any inaccuracies or omissions."
  },
  "760": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant chemotherapy is routinely recommended for all stage IIA (T2b, N0) patients regardless of risk factors, omitting the nuance that it is typically considered in the presence of high-risk features; this is a moderate factual error and overstates the standard of care."
  },
  "761": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the mechanism as inhibition of DNA (nucleic acid) synthesis, explains the clinical context, and accurately links atovaquone’s action to impaired nucleic acid synthesis, fully matching the reference answer with no errors or omissions."
  },
  "762": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies NSAIDs as the class, explains COX inhibition as the mechanism, and links to prostaglandin synthesis; all key facts from the reference are included with relevant, accurate elaboration."
  },
  "763": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies JAK1/2 as the molecular target of ruxolitinib, which is indeed used for steroid-refractory GVHD, but the reference answer specifies TNF as the direct target, likely referring to agents like infliximab or etanercept. The model covers the clinical context and mechanism for JAK inhibition but misses the reference's key fact, resulting in a moderate omission."
  },
  "764": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the inhibition of both COX-1 and COX-2, covering over 90% of key facts; however, it does not specifically name \"Prostaglandin G/H Synthase 1 (COX-1)\" as the primary target, which is a minor omission."
  },
  "765": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly identifies the indication for chemotherapy in this scenario, and provides relevant guideline context, but it contains a minor inaccuracy by labeling the tumor as T2 (when it is T1b), and slightly overstates that endocrine therapy alone is also reasonable, whereas the reference answer is more definitive about recommending chemotherapy."
  },
  "766": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly explains the mutual exclusivity of driver mutations, and emphasizes guideline-based practice to rule out other actionable mutations before starting an ALK inhibitor. However, the initial \"No\" is somewhat misleading compared to the reference's clear \"Yes,\" representing a minor wording inaccuracy that does not alter the overall clinical meaning."
  },
  "767": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug as chloroquine and explains its mechanism (inhibition of heme detoxification), but it does not directly state \"inhibition of nucleic acid synthesis\" as the primary mechanism, which is the key fact in the reference answer. The explanation is accurate but focuses on an upstream effect rather than the direct mechanism asked."
  },
  "768": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing re-resection, appropriately qualifying the role of adjuvant radiotherapy, and referencing guidelines; all additional content is correct and clinically relevant."
  },
  "769": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that surgery alone is inadequate and that adjuvant therapy is needed, but it emphasizes radiotherapy as the primary addition, whereas the reference gives equal weight to chemotherapy or chemoradiation; this is a minor wording inaccuracy but does not alter the overall clinical message."
  },
  "770": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the use of synthetic estrogens or progestins and their action via nuclear hormone receptors, but it incorrectly emphasizes the estrogen receptor pathway rather than specifically identifying the progestational hormone receptor as in the reference answer; this represents a moderate factual inaccuracy."
  },
  "771": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the surveillance schedule is specifically for post-surgical patients and not for those treated with definitive radiotherapy, which is a moderate factual error. While it provides some correct details about surveillance, it misrepresents eligibility, omitting the key fact that both groups qualify for the described schedule."
  },
  "772": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism (inhibition of PBPs and cell wall synthesis inhibitors) but does not use the broader term \"enzyme inhibitors\" as in the reference; it covers most key facts but misses the general class specified in the reference."
  },
  "773": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly denies that both tumors must be independently considered potentially curable for the two-primary approach, which is a key fact in the reference; while the explanation is detailed and mostly accurate, this central omission and initial inaccuracy lower the score."
  },
  "774": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging and perioperative therapy indications, and clearly states that Stage IIB is not excluded; all additional details are correct and clinically relevant."
  },
  "775": {
    "score": 2.0,
    "explanation": "2: The answer correctly identifies azoles (specifically isavuconazole) as effective against Mucorales and discusses drug-drug interactions, but it incorrectly focuses on P-glycoprotein and CYP3A4 inhibition rather than the key fact that isavuconazole inhibits renal OCT2. This is a moderate factual omission regarding the specific transporter and its clinical significance."
  },
  "776": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizes the need for dose reduction and monitoring with larotrectinib, and appropriately advises against entrectinib due to lack of data. However, it is slightly more permissive than the reference regarding larotrectinib's appropriateness, lacking the reference's emphasis on caution and individualized risk assessment, which constitutes a minor omission."
  },
  "777": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate staging details, and includes relevant, correct additional information without any inaccuracies or omissions."
  },
  "778": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "779": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies covalent binding to PBPs (specifically PBP3), and provides additional accurate, relevant mechanistic detail without any inaccuracies or omissions."
  },
  "780": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale and supporting evidence, and includes relevant guideline recommendations without any inaccuracies or omissions."
  },
  "781": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as beta-lactam antibiotics and accurately describes their mechanism, but it does not use the broader term \"enzyme inhibitors\" as in the reference; otherwise, all key facts are present and explanations are clinically relevant."
  },
  "782": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and mechanism of action for ivermectin, but incorrectly names \"glutamate-gated chloride channels\" instead of the reference answer \"GABA A receptors,\" missing the specific molecular target required by the question. Most key facts are covered, but the main target is inaccurately identified."
  },
  "783": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale for prioritizing definitive radiotherapy over surgery, clarifies the limited role of SABR in stage III disease, and provides accurate, clinically relevant details without inaccuracies or omissions."
  },
  "784": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides additional relevant detail, but its initial conditional language (\"should be considered\" and \"not universally required\") slightly weakens the clear prioritization stated in the reference. However, it correctly emphasizes stabilization when fracture risk is high and discusses exceptions, with no inaccuracies or unsafe advice."
  },
  "785": {
    "score": 0.0,
    "explanation": "0: The model answer incorrectly identifies the class of enzyme inhibition as \"competitive inhibition\" of lanosterol 14-α-demethylase, whereas the reference specifies \"squalene monooxygenase inhibitors\"; this is a major factual error regarding the target enzyme and class."
  },
  "786": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that SBRT is typically favored over surgery in marginally operable patients, which contradicts the reference's clear prioritization of surgery unless contraindicated; while it provides relevant details, this represents a moderate factual error regarding standard management."
  },
  "787": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing that sequential therapy is preferred and concurrent chemoradiation is not standard due to toxicity, but it slightly underplays that concurrent chemoradiation is an appropriate option in select patients and is often preferred for local control if tolerated, as stated in the reference."
  },
  "788": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key clinical facts about the mechanism of ergot derivatives in migraine (serotonin 5-HT1B/1D agonism), but it omits the reference answer’s focus on dopamine receptor interactions as most directly relevant, which is a moderate omission. The explanation is otherwise accurate and relevant."
  },
  "789": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the sodium-chloride symporter in the distal convoluted tubule as the target, which is accurate for thiazide and thiazide-like diuretics, but it does not mention potassium channels as specified in the reference answer; thus, it covers most but not all key facts."
  },
  "790": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the general indication for chemotherapy, the need to avoid anthracyclines, consideration of alternative regimens, and the importance of individualized, multidisciplinary risk assessment due to cardiac comorbidity. No inaccuracies or omissions are present."
  },
  "791": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the standard of care for PD-L1 1–49%, the risks of chemotherapy in heart failure, and the limited benefit of ICI monotherapy in this subgroup. However, it incorrectly states that ICI monotherapy is not appropriate, whereas guidelines allow it for PD-L1 ≥1% if chemo is unsuitable, making this a moderate factual error."
  },
  "792": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dopamine reuptake inhibitors as the primary class, accurately explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "793": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and explains the mechanism, but does not specify COX-1 as the most directly relevant isoform, which is required for full alignment with the reference answer."
  },
  "794": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that the mechanism is not fully understood and provides accurate, relevant details about sodium oxybate and its likely actions, but it goes beyond the reference by specifying GABA-B agonism, which, while widely accepted, is not strictly required by the reference's \"unknown\" description; this constitutes a minor wording inaccuracy."
  },
  "795": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts (enzyme inhibition, beta-lactam/penicillin class, mechanism of action) and provides relevant clinical context, but the primary pharmacological class requested is \"enzyme inhibitors,\" which is not explicitly stated as the main answer—this is a minor wording inaccuracy."
  },
  "796": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug (rifampin), its mechanism (binding the beta subunit of RNA polymerase to inhibit transcription), and provides the drug class as \"RNA polymerase inhibitor,\" which is accurate but slightly less broad than the reference answer \"nucleic acid synthesis inhibitors\"; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "797": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes standard surveillance, and correctly states that FDG-PET/CT and brain MRI are not routinely indicated. Additional content is factually correct, clinically relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "798": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts (inhibition of nucleic acid synthesis) and provides accurate, relevant additional detail about hypomethylating agents, but it does not explicitly state \"inhibition of nucleic acid synthesis\" as the primary mechanism, which is a minor omission in wording."
  },
  "799": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the 26S proteasome, and provides additional accurate, relevant explanations without any inaccuracies or omissions."
  },
  "800": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, including the general recommendation for broad molecular profiling in squamous NSCLC under certain circumstances, the importance of PD-L1 testing, and the relevance of clinical context (age, smoking history, tissue sufficiency). However, it overemphasizes exceptions and nuances, which, while accurate, slightly obscure the current trend toward broader testing in advanced disease regardless of histology, as stated in the reference. No unsafe or incorrect statements are present."
  },
  "801": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "802": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism (mast cell stabilization and inhibition of degranulation) but does not identify the broader mechanism-of-action class \"Biological Response Modifiers,\" omitting a key fact from the reference answer."
  },
  "803": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by stating there is no difference in imaging frequency, omitting the key fact that radiotherapy requires more frequent (every 3–6 months) imaging than surgery (every 6 months). This is a major inaccuracy."
  },
  "804": {
    "score": 3.0,
    "explanation": "3: The model answer covers the importance of magnesium as a cofactor in renal acid-base handling and its correction of hypomagnesemia, but it overemphasizes the direct alkalinizing effect of the sulfate anion, which is not the primary pharmacological property relevant here; the key fact—acid-base activity—is somewhat obscured by this, constituting a minor inaccuracy and partial omission."
  },
  "805": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that CT every 6 months is sufficient, whereas guidelines recommend every 3–6 months for the first 2–3 years; this is a moderate factual omission. The rest of the content is relevant and accurate, but the key frequency detail is not fully addressed."
  },
  "806": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that RET-targeted therapy is preferred over chemotherapy, and provides relevant, up-to-date guideline and drug information without inaccuracies or omissions."
  },
  "807": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that surgery is not the preferred option, contradicting the reference answer and guidelines; it provides relevant context and considerations but underemphasizes the guideline-based preference for surgery in completely resectable, fit patients, constituting a moderate factual inaccuracy."
  },
  "808": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the clinical scenario and mechanism of cantharidin but fails to specify \"enzyme inhibitor\" as the pharmacologic class, instead using \"vesicant\" and \"keratolytic agent,\" which are less precise for the mechanism described in the reference. No unsafe statements, but a key classification is omitted."
  },
  "809": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class (NSAIDs), mechanism (COX inhibition), and clinical context, but does not explicitly use the term \"cyclooxygenase inhibitors\" as in the reference; otherwise, all key facts are present with only a minor wording difference."
  },
  "810": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant facts, such as the current FDA approval status and the issue of coexisting mutations, but it incorrectly states that amivantamab-vmjw plus lazertinib is not appropriate first-line therapy solely due to the presence of a KRAS mutation, which is inaccurate; the main reason is lack of first-line approval, not KRAS status, and it overstates the exclusion of such patients from EGFR-targeted therapy, omitting that EGFR remains the primary driver for therapy selection."
  },
  "811": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies phospholipase A2 as the enzyme inhibited by glucocorticoids, but the question specifically asks for the enzyme class central to leukotriene formation from arachidonic acid, which is lipoxygenase. The answer covers much of the relevant physiology but misses the key fact required by the question."
  },
  "812": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly emphasizes the need for orthopedic stabilization and radiotherapy before systemic therapy, and provides relevant rationale. However, stating these interventions can be done \"before or concurrently\" with systemic therapy introduces a minor wording inaccuracy, as the reference specifies they should be performed prior, not concurrently."
  },
  "813": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "814": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that interrupting and switching to a TRK inhibitor is the preferred and only correct approach, whereas the reference answer clearly states that both completing current therapy or switching are acceptable and should be individualized; this is a moderate factual error and overstates guideline recommendations."
  },
  "815": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies enzymes as the principal molecular targets and provides relevant examples, but omits explicit mention of transporters, which are also key as per the reference answer; otherwise, the content is accurate and clinically relevant."
  },
  "816": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the indication, rationale, and guideline support for radiotherapy in this scenario, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "817": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that comprehensive molecular profiling is presumed regardless of smoking status, and provides correct, relevant guideline context without inaccuracies or omissions."
  },
  "818": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the key enzyme and explains the mechanism, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary isoform responsible for anti-inflammatory effects, which is a minor omission."
  },
  "819": {
    "score": 5.0,
    "explanation": "5: The model answer correctly states that adjuvant pembrolizumab is indicated for all eligible TNBC patients who received neoadjuvant pembrolizumab, regardless of pathological response or additional high-risk features, and provides accurate, up-to-date references; there are no inaccuracies or omissions."
  },
  "820": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that neoadjuvant therapy is indicated for cT1cN0 triple-negative breast cancer and not reserved only for HER2-positive or node-positive cases. Additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "821": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant elaboration, and contains no inaccuracies or omissions."
  },
  "822": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of cell wall synthesis and provides accurate, relevant detail about beta-lactam antibiotics, but it does not explicitly use the broader term \"enzyme inhibitors\" as in the reference, representing a minor omission in terminology."
  },
  "823": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the appropriateness of EGFR TKI use in poor performance status due to tumor burden, the specific mutations, and agent options. Additional content is accurate, relevant, and guideline-based, with no inaccuracies or omissions."
  },
  "824": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of the mechanism (mucoadhesive and lubricating effect) but does not explicitly use the key term \"demulcent activity\" as in the reference answer; it covers most key facts but omits the precise pharmacological term required."
  },
  "825": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the role of phospholipase A2 inhibition by corticosteroids but fails to directly identify the lipoxygenase pathway as the most direct target for reducing leukotriene-mediated inflammation, as required by the question; it covers most key facts but omits the specific pathway asked."
  },
  "826": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferon-alpha as the drug and explains its mechanism via activation of protein kinases (notably PKR), but it does not explicitly state \"RNA replicase enzymes\" as the primary molecular target, missing the key fact from the reference answer. The explanation is otherwise accurate and relevant."
  },
  "827": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism and provides relevant detail, but it names \"β-lactam antibiotics\" (a drug class) rather than the general pharmacological class \"enzyme inhibitors\" as required by the question and reference, omitting the key fact needed for full credit."
  },
  "828": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the specific class (beta-lactam antibiotics) and provides an accurate mechanism, but it omits the broader pharmacological class \"enzyme inhibitors\" as required by the reference answer, covering about 70-89% of key facts."
  },
  "829": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the rarity of EGFR mutations in squamous cell carcinoma and the need for careful histological confirmation, but it overstates the appropriateness of osimertinib in pure squamous histology and does not sufficiently emphasize that standard first-line therapy excludes EGFR TKIs except in rare, ambiguous cases, leading to a moderate omission."
  },
  "830": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies corticosteroids as the class with a similar mechanism, rather than lipoxygenase inhibitors, which directly inhibit leukotriene production; while the mechanistic explanation is detailed and mostly accurate, it misses the key fact that lipoxygenase inhibitors are the correct answer, covering about 70-89% of the reference content."
  },
  "831": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant additional details without any inaccuracies or omissions."
  },
  "832": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "833": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 instead of CYP2D6 as the primary enzyme implicated, which is a moderate factual error; while the explanation is detailed, it does not address the key fact from the reference answer."
  },
  "834": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "835": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies PDGFRA as the molecular target inhibited by imatinib in FIP1L1-PDGFRA–positive HES, but it does not mention KIT (the reference answer), which is specifically asked for; thus, it covers most but not all key facts."
  },
  "836": {
    "score": 1.0,
    "explanation": "1: The model answer is detailed and accurate regarding leucovorin's mechanism, but it does not mention \"phosphate chelating activity,\" which is the sole key fact in the reference answer; thus, it covers <40% of the required content."
  },
  "837": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional rationale, and contains no inaccuracies or omissions."
  },
  "838": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the compound and its antimicrobial mechanism as cell membrane disruption, but it does not mention enzyme interactions, which is the key fact in the reference answer; thus, it covers about 70-89% of the required content."
  },
  "839": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, discusses the risks of misclassification, and appropriately describes rare exceptions, with no inaccuracies or omissions."
  },
  "840": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly identifies the muscarinic M2 receptor as the answer, which is a major inaccuracy, despite a partially correct discussion; it fails to name the beta-1 adrenergic receptor, which is the key fact required."
  },
  "841": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies isotretinoin and its general mechanism but incorrectly names the retinoic acid receptor (RAR) instead of the retinoid X receptor (RXR) as the specific nuclear receptor directly modulated, missing the key fact required by the reference."
  },
  "842": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant additional detail, and contains no inaccuracies or omissions."
  },
  "843": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism as modulation of gene expression via nuclear receptor binding, which is a more specific form of \"modulation of enzyme-mediated biological processes,\" and provides accurate, relevant details. However, it does not explicitly use the broader reference phrasing and may slightly over-specify the mechanism, but there are no clinically significant omissions or inaccuracies."
  },
  "844": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that both observation and adjuvant systemic therapy are appropriate, and provides additional relevant, correct, and guideline-based context without any inaccuracies or omissions."
  },
  "845": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferon-alpha and its immunomodulatory mechanisms, but the class given (\"cytokine receptor agonist\" or \"immunomodulatory cytokine\") does not match the reference answer \"biological response modifiers,\" omitting the key classification term required."
  },
  "846": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that adjuvant systemic therapy is not universally indicated after R0 resection and completed neoadjuvant therapy, and that surveillance is appropriate unless high-risk features or incomplete therapy exist; all additional content is correct and clinically relevant."
  },
  "847": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT or brain MRI is not indicated, and provides relevant guideline-based details without inaccuracies or omissions."
  },
  "848": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of cell wall synthesis and accurately explains the role of PBPs, but it does not explicitly use the term \"enzyme inhibition\" as in the reference, which is a minor omission."
  },
  "849": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that brain MRI is recommended as a mandatory staging assessment for stage II NSCLC regardless of symptoms, and incorrectly states it is only required if neurologic symptoms are present, which is a moderate factual error."
  },
  "850": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and provides accurate, relevant clinical context, but does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference; this is a minor omission since both COX-1 and COX-2 are inhibited, but COX-2 is more directly linked to inflammation."
  },
  "851": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on matrix metalloproteinases (MMPs) rather than interleukin-6 antagonists, omitting the key reference fact about IL-6 pathway inhibition; while the explanation is relevant to wound healing, it does not address the specific cytokine pathway asked in the question."
  },
  "852": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts (mechanism, activation by viral kinases, inhibition of DNA polymerase, relevant drug examples) and provides clinically relevant detail, but does not explicitly use the term \"DNA polymerase inhibitors\" as in the reference, which is a minor wording inaccuracy."
  },
  "853": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies re-resection as the preferred approach and radiotherapy as an option if re-resection is not feasible, but it incorrectly states that radiotherapy should not be considered if surgery is possible, missing the nuance that radiotherapy can be considered as an alternative even when re-resection is feasible (albeit as a lower-category recommendation)."
  },
  "854": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging change to IIIB, and clearly describes the impact on perioperative therapy eligibility, with no inaccuracies or omissions."
  },
  "855": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and relevant rationale, and contains no inaccuracies or omissions."
  },
  "856": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), including both COX-1 and COX-2, as the molecular targets, covering over 90% of the key facts. However, it does not specify \"Prostaglandin G/H Synthase 1 (COX-1)\" as the single, most precise answer, representing a minor omission in specificity."
  },
  "857": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant explanations, cites guidelines, and contains no inaccuracies or omissions."
  },
  "858": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 instead of CYP2C9 as the key enzyme to monitor, which is a moderate factual error, though the rest of the explanation is relevant and accurate."
  },
  "859": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and cites guidelines, but incorrectly states that surveillance intervals are the same for both groups, missing the reference answer's distinction that radiation-treated patients require more frequent surveillance due to higher recurrence risk."
  },
  "860": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the cytochrome P450 system as the relevant enzyme family but specifies CYP3A4 rather than the reference's CYP1A, missing the key fact about the specific isoenzyme involved; otherwise, the explanation is accurate and relevant."
  },
  "861": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate explanation of vitamin A’s role in photoreceptor function and night vision, but it does not directly state the key mechanism from the reference—free radical scavenging (antioxidant effect)—as the best explanation, instead focusing on the retinoid cycle and rhodopsin regeneration."
  },
  "862": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies proton pump inhibitors as the drug class sharing the molecular target, explains the mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "863": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies phospholipase A₂ as the directly inhibited enzyme, whereas the reference specifies lipoxygenase; however, it covers most key clinical facts and the mechanism of glucocorticoid action, with no unsafe statements."
  },
  "864": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the enzyme (cyclooxygenase/COX) and the mechanism (inhibition of conversion of arachidonic acid to prostaglandins), but does not specify COX-2, which is the more relevant isoform for anti-inflammatory effects; otherwise, all key facts are present and explanations are accurate."
  },
  "865": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why perioperative therapy is unsuitable, and appropriately recommends nonsurgical modalities; all additional content is correct and clinically relevant."
  },
  "866": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies 5-HT1B/1D agonism (triptans) as the prophylactic mechanism, whereas the reference specifies 5-HT2 antagonism (methysergide) for prevention; it covers some relevant migraine pathophysiology but omits the key fact and mechanism, constituting a moderate factual error."
  },
  "867": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, addresses alternative options, and provides relevant guideline references without any inaccuracies or omissions."
  },
  "868": {
    "score": 2.0,
    "explanation": "2: The model answer describes the mechanism of somatostatin analogs rather than dopamine agonists, which is a moderate factual error since the question and reference specify dopamine agonism; however, the explanation is otherwise relevant and not unsafe."
  },
  "869": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts, correctly identifying praziquantel and its proposed mechanism, but it does not explicitly state that the precise molecular mechanism is unknown, which is the main point of the reference answer; instead, it emphasizes the leading hypothesis, resulting in a minor omission."
  },
  "870": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate rationale, cites relevant guidelines, and contains no inaccuracies or omissions."
  },
  "871": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of corticosteroids and identifies phospholipase A2 inhibition, but it does not mention lipoxygenase inhibition, which is the specific enzyme asked for in the reference answer; thus, it covers most but not all key facts."
  },
  "872": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly explains the rationale for both re-operation and radiotherapy, addresses the impact of COPD and borderline pulmonary function, and emphasizes multidisciplinary assessment. There are no inaccuracies or omissions."
  },
  "873": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging, standard management, and exceptions, and provides relevant references without any inaccuracies or omissions."
  },
  "874": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies chelation as the principal pharmacological property, explains its mechanism, and relates it to the pathophysiology, but includes speculative content about Wilson disease that is not in the reference and is not strictly required, making the answer slightly less concise than ideal."
  },
  "875": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that concurrent chemoradiation is not recommended due to high risk, and discusses alternative, less aggressive approaches; there are no inaccuracies or omissions."
  },
  "876": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that absence of distant metastases (M0) is required for eligibility, and that presence of M1 disease changes management to palliative systemic therapy. No inaccuracies or omissions are present."
  },
  "877": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on cyclooxygenase (COX) inhibition, which is the main mechanism for most NSAIDs, but the question specifically asks for the enzyme involved in cyclic nucleotide signaling (phosphodiesterase), as referenced in the stem and the reference answer. The model omits this key fact and does not directly address the molecular target described, constituting a moderate omission."
  },
  "878": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that pleurodesis alone is insufficient and systemic therapy is necessary, with accurate rationale and relevant, correct additional details; there are no inaccuracies or omissions."
  },
  "879": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the syndrome, drug, mechanism, and class (pituitary/growth hormone receptor agonist), and provides relevant, accurate additional detail without any errors or omissions."
  },
  "880": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately clarifies that adjuvant therapy does not inherently imply additional high-risk features, and provides relevant, correct guideline context without introducing inaccuracies or omissions."
  },
  "881": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism and provides accurate, relevant explanations, but does not explicitly state \"cholinesterase inhibitors\" as the class mediating the effect, instead using the broader term \"parasympathomimetic (cholinomimetic) agents,\" which is slightly less precise than the reference answer."
  },
  "882": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical syndrome, mechanism, and specific drugs used, but it incorrectly names the drug class as \"antimalarial agents\" rather than \"enzyme inhibitors\" as required by the question, missing the key fact that the mechanism is classified by enzyme inhibition rather than therapeutic class."
  },
  "883": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts, correctly identifies the receptor class (steroid hormone/nuclear/glucocorticoid receptor), and provides accurate, relevant mechanistic detail with no errors or omissions."
  },
  "884": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why concurrent chemoradiation is not appropriate in this scenario, and provides relevant, guideline-based alternatives without any inaccuracies or omissions."
  },
  "885": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides accurate and clinically relevant rationale, cites guidelines, and contains no inaccuracies or omissions."
  },
  "886": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough, guideline-based rationale for H&P and chest CT every 6 months, but it omits the key fact that adjuvant radiotherapy escalates surveillance needs to every 3–6 months (as for stage III), thus missing the most clinically relevant point from the reference."
  },
  "887": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly states that systemic therapy alone is insufficient, and that sequential chemoradiation is preferred, with rationale and guideline support; all additional content is accurate and clinically relevant."
  },
  "888": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies CYP2C9 inhibitors as the relevant class and provides accurate, clinically relevant context, but adds extra detail about the mechanism (competitive inhibition) not specified in the reference. There are no inaccuracies, but the focus could be tighter on the reference answer."
  },
  "889": {
    "score": 5.0,
    "explanation": "5: The model answer correctly explains that external-beam radiotherapy in stage IIIA NSCLC is standard management and does not necessarily imply endobronchial obstruction or locoregional recurrence, covering all key clinical facts with accurate, relevant elaboration and no errors."
  },
  "890": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies JAK3 as the molecular target, thoroughly explains the clinical context, mechanism, and relevant cytokines, and provides accurate, clinically relevant extra information without any errors or omissions."
  },
  "891": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including guideline distinctions and risk stratification, but incorrectly states that omission of brain MRI in stage II NSCLC does not compromise adequacy, which contradicts the reference answer and current recommendations; this represents a moderate factual inaccuracy."
  },
  "892": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but introduces a significant caveat regarding the presence of other driver mutations (e.g., KRAS), suggesting osimertinib is not appropriate if such mutations are present, which is not supported by the reference answer. This constitutes a moderate omission and introduces ambiguity, lowering the score."
  },
  "893": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of transpeptidation via binding to penicillin-binding proteins and links this to beta-lactam antibiotics, but it does not explicitly use the term \"transpeptidase inhibitors\" as in the reference, which is a minor wording omission."
  },
  "894": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies bismuth subsalicylate and describes its anti-secretory, anti-inflammatory, and protective actions, but it incorrectly emphasizes prostaglandin inhibition as the primary mechanism, whereas the reference focuses on acid-base activity and local pH alteration; thus, it covers 70-89% of key facts but misprioritizes the main mechanism."
  },
  "895": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the enzyme inhibited by NSAIDs and explains its role, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference; this is a minor omission since most topical NSAIDs are non-selective."
  },
  "896": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the molecular target as the interleukin-6 receptor and provides relevant, accurate clinical context, but it does not specify the \"alpha subunit\" as in the reference answer, which is a minor omission."
  },
  "897": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, including both COX-1 and COX-2, which is accurate for aspirin. However, it does not specify COX-2 as the primary target for anti-inflammatory effects, representing a minor omission compared to the reference."
  },
  "898": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and accurate explanation of PDE3 inhibitors, but this is not the drug class described in the question stem (which specifies inhibition of a G-protein coupled receptor pathway, i.e., alpha-adrenergic antagonists). The answer omits the key fact that the drug class is alpha-adrenergic antagonists and instead describes a different, less directly relevant mechanism, constituting a moderate factual error."
  },
  "899": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but introduces the idea of prophylactic intervention in asymptomatic patients, which is not standard and not supported by the reference; this constitutes a moderate factual inaccuracy and overstates the indications for endobronchial therapy."
  },
  "900": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD2 as the molecular target, provides accurate mechanistic reasoning, and includes only clinically relevant, factually correct additional information without any inaccuracies or omissions."
  },
  "901": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale for immediate switching to ROS1-targeted therapy and cites guidelines, but it incorrectly states that completion of current therapy is not recommended, directly contradicting the reference answer, which allows either approach; this constitutes a moderate factual error."
  },
  "902": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the hepatic metabolism and contraindications of both drugs, and clearly concludes that neither is appropriate in severe hepatic impairment, with no inaccuracies or omissions."
  },
  "903": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly prioritizing palliative radiotherapy for immediate localized symptom control and noting the role of systemic therapy, but introduces nuanced symptom stratification not present in the reference. This extra detail is accurate and relevant, but the conditional framing slightly dilutes the clear prioritization stated in the reference, constituting a minor wording inaccuracy."
  },
  "904": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies chylomicrons as the bypassed molecular component and explains the mechanism, but it does not explicitly mention \"chylomicron structural macromolecules\" (e.g., apolipoproteins, phospholipids) as in the reference; this is a minor omission."
  },
  "905": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the contraindication of standard chemotherapy in significant hepatic impairment, the rationale regarding drug metabolism and toxicity, and the consideration of surgery as an alternative. It also appropriately contextualizes the modest benefit of chemotherapy in cT1c, cN0 TNBC and individualization of care, with no inaccuracies or omissions."
  },
  "906": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical diagnosis and the mechanism of action for corticosteroids, but it does not match the reference answer, which specifies estrogen receptor agonists as the class relevant to the question stem. The model provides accurate information for corticosteroids but misses the key fact that the described mechanism in the question refers to estrogen, not corticosteroids."
  },
  "907": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cytochrome P450 (specifically CYP3A4) as the inhibited enzyme system and provides relevant clinical context, but omits mention of CYP2C19, which is also important for some triazoles like voriconazole; this is a minor omission."
  },
  "908": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the clinical scenario, drug class, mechanism, and the role of ABC transporters in resistance, but incorrectly identifies P-glycoprotein (ABCB1) as the most relevant transporter instead of BCRP (ABCG2), which is specifically referenced in the correct answer. This constitutes a moderate factual error."
  },
  "909": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies topoisomerase IV as a molecular target and provides accurate, relevant extra information, but does not explicitly single out topoisomerase IV as the sole answer (as in the reference), instead listing both DNA gyrase and topoisomerase IV; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "910": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining that M1a status generally precludes curative resection unless both lesions are unequivocally proven to be separate primaries, and provides additional, relevant detail without inaccuracies or omissions."
  },
  "911": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, drug (thalidomide), and its immunomodulatory action, but incorrectly names TNF-α as the most direct molecular target, omitting VEGF-A, which is specified in the reference as the key target; otherwise, the reasoning is accurate and relevant."
  },
  "912": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies tissue plasminogen activators as the relevant class, explains the clinical scenario, and accurately describes defibrotide’s mechanism, but the final answer is less specific than the reference and could be clearer by directly stating \"tissue plasminogen activators\" as the primary class."
  },
  "913": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough, guideline-based rationale for promptly switching to ALK inhibitor therapy, but it omits that completing the current systemic therapy before switching is also an acceptable option per the reference. This represents a moderate omission of a key fact."
  }
}